

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

The effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning maneuvers in patients with benign paroxysmal positional vertigo : protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026711
Article Type:	Protocol
Date Submitted by the Author:	20-Sep-2018
Complete List of Authors:	wu, Peixia; Eye & ENT Hospital of Fudan University Cao, Wenzhu; Eye and ENT Hospital of Fudan University, intensive care unit Hu, Yan; School of Nursing, Fudan University Li, Huawei; Eye & ENT Hospital of Fudan University, Department of Otorhinolaryngology
Keywords:	benign paroxysmal positional vertigo, vestibular rehabilitation, dizziness, randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4 **The effects of vestibular rehabilitation, with or without betahistine, on managing residual**
5
6 **dizziness after successful repositioning maneuvers in patients with benign paroxysmal**
7
8 **positional vertigo : protocol for a randomized controlled trial**
9

10 Wu Peixia,¹ Cao Wenzhu,² Hu Yan,³ Li Huawei⁴

11
12
13 1. Department of operation room, Eye and ENT Hospital of Fudan University, Shanghai, China

14
15
16 2. Intensive care unit, Eye and ENT Hospital of Fudan University, Shanghai, China

17
18 3. School of Nursing, Fudan University, Shanghai, China

19
20
21 4. Department of Otorhinolaryngology, Eye and ENT Hospital of Fudan University, Shanghai,
22
23 China

24
25 Co-Corresponding author: Dr. Li Huawei, Head of Department of Otorhinolaryngology, Eye and
26
27 ENT Hospital of Fudan University, No.83 Fenyang Road, Shanghai, 200031, China; Tel:
28
29 86-21-64377134-669; E-mail: hwli@shmu.edu.cn

30
31
32 Co-Corresponding author: Dr. Yan Hu, President of School of Nursing, Fudan University, No.305
33
34 Fenling Road, Shanghai, 200031, China; E-mail: fudanhuyan@163.com

35
36
37 **Contributors** All authors have made an intellectual contribution to this protocol. Li Huawei is the
38
39 principal investigator of the trial, with full responsibility for the project. Wu PX, Cao WZ and Hu
40
41 Yan conceived the design, developed the protocol and wrote the first draft of this manuscript. Li
42
43 Huawei and Hu Yan revised and approved the final version of the study protocol and the final
44
45 manuscript. Li Huawei and Hu Yan are co-corresponding authors whom contributed this paper
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
equally.

Abstract

Introduction

Benign paroxysmal positional vertigo (BPPV) is recognized as the leading cause of periphery dizziness in adults. Canalith repositioning procedure (CRP) can effectively treat BPPV. However, a certain group of patients experience residual dizziness (RD) even after successful CRP, bringing a significantly negative impact on their daily function and quality of life. Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness and has been applied in patients with different vestibular disorders. However, the effectiveness of VR specifically targeted RD post BPPV is unknown. This study aims to investigate the effectiveness of VR, compared with betahistine or VR plus betahistine, in patients experiencing RD after successful CRP.

Methods and analysis

A randomized single-blinded controlled trial will be carried out to determine the effectiveness of VR, compared with betahistine or VR plus betahistine, in mitigating RD and improving balance function. Patients with BPPV after successful CRP and complain of experiencing RD will be recruited. Participants will be randomized into one of three groups to receive VR or betahistine or VR plus betahistine. There will be 61 participants in each group. Primary outcomes are changes of patients' daily function measured by Vestibular Activities and Participation (VAP) questionnaire and balance ability assessed by computerized dynamic posturography (CDP). Secondary outcomes will assess quality of life, otolith function, and duration of symptoms.

Outcome measures will be taken at baseline, 4 -week, 8-week and 12-week post randomization.

This study has the potential to arrive at stopping unnecessary anti-vertigo drugs prescriptions and

1
2
3 may lead to the consensus of using VR as the first-line treatment for RD in patients with BPPV.
4
5

6 **Ethics and dissemination**

7

8 This trial received ethics approval from Institute Review Board of Eye & ENT Hospital of Fudan
9
10 University (2017046). Study results will be disseminated through peer-reviewed journals and
11
12 conferences.
13
14

15
16 ClinicalTrials.gov identifier: NCT03624283
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study

► To our knowledge, this is the first randomized controlled trial evaluating the effects of vestibular rehabilitation, compared with betahistine or VR in addition to betahistine, on managing residual dizziness after successful CRP in patients with BPPV.

► Both subjective and objective outcome measures are comprehensively assessed with reasonable long follow-up time. In Particular, patients' activities and participation aspect based on International Classification of Functioning, Disability and Health (ICF) framework are evaluated. Such a trial will be able to fully reflect the efficacy of proposed intervention.

► For practical reason, there is no sham or placebo or no treatment as comparison group in this study; therefore, the study cannot tell whether participants improve simultaneously or how the three interventions may work in different ways to change outcomes.

INTRODUCTION

Benign paroxysmal positional vertigo (BPPV) is the leading cause of peripheral dizziness, with a prevalence from 10.7 to 64 per 100,000 populations and a lifetime prevalence of 2.4%.[1] The onset time is most commonly between the fifth and seventh decade of life, but BPPV could occur at any age.[2] Two theories --- cupulolithiasis[3] and canalithiasis[4], are among the most widely accepted theories that elucidate the pathophysiology of BPPV. Canalithiasis has gained wider acceptance among the scientific field due to the symptoms being better explained.[5] According to the canalolithiasis hypothesis, BPPV is caused by free otoconia dislodged from the utricular macula and entering into the semicircular canal, which therefore provokes an inappropriate flow of endolymph whenever the head is rotated in the plane of the affected canal.[4] Although any of the three semicircular canals can be affected, the posterior semicircular canal BPPV is the most common, followed by horizontal canal BPPV. Treatment of BPPV is based on the performance of canalith repositioning procedure (CRP), with the aim of repositioning the displaced particles from the affected canal to their original location.[6] CRP has long emerged as a mainstay of therapy and now is well established as the gold treatment for BPPV.[7] Posterior canal BPPV can be treated by performing Epley's maneuver or Semont's liberatory maneuver. For horizontal canal BPPV, Barbecue rotation or Gufoni's maneuvers have been shown effective.

Despite the fact that CRP can provide rapid relief of vertigo sensation in BPPV patients, residual symptoms may remain even after disappearance of typical vertigo and nystagmus following a successful CRP. These residual symptoms, also referred residual dizziness (RD), imply a non-specific sensation of unsteadiness, lightheadedness, disorientation, fogginess or drowsiness.[8] The reported incidence of RD ranges from 29.6% to 76.9% and the duration of RD can range from

1
2
3 a few days to several months.[8-12] Several Authors reported that RD symptoms may persist up to
4
5 more than 3 months [13, 14], bringing adverse physical and psychological consequences to these
6
7 patients.
8
9

10
11 Different pathophysiological mechanisms have been proposed to explain the presence of RD but
12
13 the real cause remains unknown. Previously reported possible explanations included: (1) the
14
15 persistence of debris in the canal being insufficient to provoke detectable positional nystagmus or
16
17 vertigo;[11] (2) otolith dysfunction;[15, 16], (3) coexistent vestibular disease that lead to
18
19 incomplete central adaptation; (4) potential autonomic dysfunction such as orthostatic
20
21 hypotension[17], (5) persistent postural-perceptual dizziness (PPPD).[18]
22
23

24
25 Dizziness increases the risk of falls or fear of falling, disturbs daily life, and results in restriction
26
27 of social activities. As a result, many people tend to avoid activities, limit their movement, and
28
29 avoid specific circumstances because of fear of provoking dizziness and unanticipated
30
31 unsteadiness attacks.[19] It is not surprised that increased postural instability was documented in
32
33 patients who experiencing RD[20, 21]. Given that high prevalence of RD after successful
34
35 repositioning and its negative impact on patient recovery, this impairment should be managed
36
37 properly.
38
39

40
41 To date, there is no agreement on how to effectively manage RD after successful CRP in patients
42
43 with BPPV. Betahistine is the most widely used medication to ameliorate dizziness, due to its
44
45 effects of increasing labyrinthine microcirculation, suppressing the increased neuronal activity in
46
47 vestibular receptor cells, afferent neurons, and vestibular nuclei.[11, 22] However, conflicting data
48
49 exists regarding the efficacy of betahistine for preventing or treating RD. Guneri., et al. [23]
50
51 evaluated the efficacy of betahistine in reducing symptoms after Epley maneuver for posterior
52
53
54
55
56

1
2
3 canal BPPV, they found 48 mg of betahistine daily intake demonstrated more effective results than
4
5
6 Epley maneuver alone or combined with placebo in improving symptoms assessed by four
7
8 different vertigo symptoms scales. On the contrary, Acar., et al.[24] carried out a randomized
9
10 controlled clinical trial to investigate the efficacy of betahistine, compared with a no medication
11
12 group, for the treatment of RD after successful CRP. After 3 and 5 days of treatment, the mean
13
14 DHI (Dizziness Handicap Inventory) scores of the groups receiving medication did not differ from
15
16 the mean DHI score of the control group, indicating betahistine did not produce any more
17
18 alleviation of RD than no treatment. However, both studies have unclear randomization sequence
19
20 generation, allocation concealment and only included subjective outcomes, suggesting more
21
22 rigorous methodology of clinical trials that including comprehensive outcomes assessment are
23
24 warranted.
25
26
27
28
29

30 Recently, non-pharmacological interventions, such as vestibular rehabilitation (VR), are
31
32 recommended as the first line of treatment for chronic vertigo.[22] VR, which has been available
33
34 since 1940s, is an exercise-based treatment consisting of varied eye, head, and body movements
35
36 designed to stimulate the vestibular system and optimize vestibular compensation.[25] Current VR
37
38 approach typically includes a combination of three different exercise components to address the
39
40 impairments or functional limitations identified during evaluation: (1) gaze stability exercises, (2)
41
42 habituation exercises, including optokinetic exercises, (3) balance and gait training in different
43
44 conditions.[26] The aim of VR is to improve the visual-vestibular interaction and increase balance
45
46 ability. It is also evidenced to contribute to an improvement in daily function and a reduction of
47
48 symptoms of dizziness.[26] The mechanism for its effectiveness is thought to rely on the
49
50 following three aspects: (1) compensation/habituation, which is a central process, refers to that
51
52
53
54
55
56
57
58
59
60

1
2
3 repeated exposure to a provocative stimulus will result in a reduction in the symptomatic response
4
5
6 to that treatment[27]; (2) adaptation, which is the recovery of the dynamic vestibulo-ocular
7
8 responses due to the ability of the vestibular system to make long-term changes in the neuronal
9
10 response to input; and (3) substitution, which is the use of other strategies to replace the lost
11
12 function.[28]

13
14
15 An updated evidence-based clinical guideline by American Academy of Otolaryngology-Head and
16
17 Neck Surgery Foundation (AAO-HSNF) points out that the clinician should offer VR in treatment
18
19 of BPPV, stating that although movement/ habituation-based VR should not be first-line treatment
20
21 modality for BPPV, it is indicated for patients who have persistent disability following CRP.[29]
22
23 VR is particularly indicated in subjects with additional impairments, such as nonspecific dizziness
24
25 and those patients with heightened fall risk.[7] A Cochrane review [30] has been undertaken to
26
27 assess the effectiveness of VR in people with symptomatic unilateral peripheral vestibular
28
29 dysfunction (UPVD) which included eight studies investigated VR in BPPV specifically,
30
31 supporting the thought that the primary intervention for BPPV should be CRP that directly treat
32
33 the condition, but movement/habituation-based VR will further aid and benefit long-term
34
35 functional recovery. A more recent review by Bressi et al.[31] proposes that a hierarchy of
36
37 interventions should be offered to people with BPPV, starting with CRP followed by
38
39 post-treatment exercises. They also indicate that CRP and VR seem to have a synergic effect in
40
41 patients with BPPV.[31]
42
43
44
45
46
47
48
49

50 While previous studies shed light on the great beneficial of VR in BPPV patients, to date, no
51
52 randomized clinical trial has been conducted to specifically investigate VR, with or without
53
54 betahistine, in dealing with RD following CRP in patients with BPPV. This study has been
55
56

1
2
3 designed with the broad aim of verifying VR as the first-line option in treating RD, which is
4
5
6 conformed to the current recommendations for best clinical practice with respect to the
7
8 implementation of VR for persons with impairments and functional limitations related to the
9
10 vestibular deficit.[26] Moreover, the present study has the potential to arrive at stopping
11
12 unnecessary anti-vertigo drugs prescriptions in BPPV patients.
13
14

15 **Aims of the study**

16
17
18 This study will investigate the effects of VR, compared with betahistine or VR plus betahistine, on
19
20 managing RD after successful CRP in patients with BPPV.
21
22

23 We hypothesize that participants in VR group, compared with participants in betahistine group,
24
25 will display fewer activities and participation restrictions and less balance inability. Moreover, we
26
27 expect that participants in VR group would experience shorter duration of residual dizziness,
28
29 better quality of life and enhanced recovery of otolith dysfunction (if any).
30
31

32
33 We also hypothesize that the effects of VR alone will be non-inferior to a combination of VR and
34
35 betahistine, in terms of outcome measures mentioned above.
36
37

38 **METHODS AND ANALYSIS**

39 **Study design, setting, and participants**

40
41
42 This study is designed as a randomized controlled prospective single-blinded trial. Outcome
43
44 assessment will be conducted by two researchers who are blinded to group allocation.
45
46

47
48 The study setting is the largest ENT-specialized hospital in China. The hospital serves a
49
50 population of about 23 million of Shanghai. It also serves as a referral center accepting patients
51
52 from all over the country.
53
54

55 The eligibility criteria are as follows: (1) diagnosed as unilateral BPPV (unilateral posterior
56
57
58
59
60

1
2
3
4 semicircular canal BPPV or horizontal semicircular canal BPPV) according to the clinical practice
5
6 guideline by AAO-HNSF in 2017[29], (2) aged 18~80 years, (3) reporting residual symptoms
7
8 after successful repositioning maneuvers. Participants will be excluded if they are: (1) confirmed
9
10 as anterior semicircular canal BPPV or multicanal BPPV, (2) recurrent BPPV, (3) with coexisting
11
12 vestibular disorders, including Meniere disease, vestibular neuritis, labyrinthitis, and peripheral
13
14 vestibular loss, (4) with severe cervical spine disease, (5) with severe cardiovascular diseases, (6)
15
16 with known cerebral vascular disease like carotid stenosis, (7) suspected of significant depression
17
18 or anxiety as defined as a score of ≥ 8 for each respective scale of Hospital Anxiety and
19
20 Depression Scale, (8) pregnant/ lactating or planning to become pregnant during the study period,
21
22 (9) those who had taken vestibulosuppressant, antihistamines, and/ or ototoxic medications in the
23
24 previous 3 months.
25
26
27
28
29

30 **Procedure**

31
32 The study protocol was reviewed and approved by the Institutional Review Board of the Eye &
33
34 ENT Hospital of Fudan University (Reference Number:2017046). Patients who are suspected of
35
36 having BPPV and visit ENT specialist are possibly eligible for this study. They will undergo Dix-
37
38 Hallpike test, roll test, and anterior canal provoking test to confirm as suffering from solely
39
40 unilateral posterior canal or horizontal canal involved. After diagnosis by ENT specialist, posterior
41
42 canal BPPV will be treated using Epley's maneuver or Semont's liberatory maneuver, while
43
44 horizontal canal BPPV will be treated with Barbecue rotation maneuvers. The same
45
46 physiotherapist applies both testing procedure and CRP maneuver. CRP is repeated up to three
47
48 times during one day. Conversion from a positive to a negative Dix-Hallpike is considered as
49
50 successful. Patients who failed when up to three CRPs have been performed will not be included
51
52
53
54
55
56
57
58
59
60

1
2
3 in this study.
4

5
6 On the second day following successful CRP, a lead investigator will contact the patient by either
7
8 telephone or Wechat. Patients will be asked whether they are experiencing residual symptoms. If
9
10 yes, they will be initially screened through telephone interview and those who meet the inclusion
11
12 criteria will be invited to participate in the study. A face-to-face interview will be arranged for
13
14 patients who express an interest in the trial, and formal written consent will be obtained from
15
16 candidates who agree to participate. Participants then are asked to fill out Hospital Anxiety and
17
18 Depression Scale (HADS), only those scored less than 8 for each respective subscale of anxiety or
19
20 depression will be considered eligible. After obtaining written consent form, the principal
21
22 investigator (Li HW) will fully review the participant's medical history, execute physical
23
24 examination and perform videonystagmography (VNG) to record nystagmus, to rule out any
25
26 central nervous system pathologies or other vestibular diseases. Whenever necessary, imaging
27
28 exam such as CT scan or MRI is supplemented to exclude inner ear and pontocerebellar lesions.
29
30 After eligibility screenings, participants then will be randomly allocated into one of three groups:
31
32 participants in Group A will perform VR exercises; Group B will be described with betahistine;
33
34 and Group C will be offered with both VR and betahistine. Outcome measures will be taken at
35
36 baseline, four-week, eight-week, and 12-week post randomization. Outcome measurements will be
37
38 executed by two independent research staff, one is responsible for apparatus-based measures and
39
40 another in charge of subjective data collecting, both of whom are unaware of the treatment
41
42 assignment until the end of the study. See figure 1 for a study flow chart.
43
44
45
46
47
48
49
50
51

52 **Randomization and blinding**

53

54 Participants will be randomized into three groups of 61 each. The randomization process will be
55
56

1
2
3 carried out by an internet-based randomization tool provided by China clinical trial registration
4
5 center. The website is accessible to public via <http://www.medresman.org/login.aspx>. The
6
7 randomization sequence will be generated automatically when the administrator logs in on the
8
9 website asking for the allocation number once an eligible patient is recruited. Participants will be
10
11 randomly allocated at a ratio of 1:1:1 with stratified by sex and age (≤ 60 years, > 60 years). As the
12
13 randomization is on-line and automatic, neither the researchers nor the patients can manipulate
14
15 which treatment the patients are receiving, therefore to ensure group allocations are randomly
16
17 assigned.
18
19
20
21
22

23 Since VR is an operational intervention, it is not possible for either patients or the physiotherapists
24
25 and physicians to be blind to allocation. However, two independent research staff will contact
26
27 patients to collect both subjective and apparatus-based data. The statistician of our trial team will
28
29 remain blind until statistical analyses are complete.
30
31
32

33 **Interventions**

34
35 Following eligible screening, participants are randomly assigned to one of three intervention
36
37 groups.
38
39

40 Participants in Group A (VR group) will perform vestibular rehabilitation exercises twice a day, 5
41
42 days per week, over a period of four weeks. The exercise protocol was developed based on clinical
43
44 experience and adapted from the previous studies. [32, 33] in which vestibular stimulated exercise
45
46 applied were shown to improve balance ability and functional performance among BPPV patients
47
48 who had undergone CRP. A dedicated physiotherapist (Wu PX) drafted the initial protocol. The
49
50 content was then reviewed by three experts with expertise in caring for patients with chronic
51
52 dizziness, and was piloted with two female and two male patients who have experienced RD post
53
54
55
56
57
58
59
60

BPPV. Participants reported no difficulties in practicing these exercises. The protocol primarily consists of three categories: oculomotor exercises, head movement exercises, gait and balance training, which is described in table 1.

Table 1 Overview of the VR program

Components	Movements	Rational
Oculomotor exercises	VORx1	Improve gaze stability and
	VORx2	vestibulo-ocular (VOR) gain
	Smooth pursuits	adaptation
	Saccades	
Head movement exercises	Shaking the head right and left, nodding the head up and down, and circumducting the head clockwise and counterclockwise; while maintaining focus on a visual target	Habituate vestibular responses and to relieve symptoms
	Static standing on varied base of support (feet apart, feet together, semi-tandem, Tandem)	Facilitate the vestibulospinal response, improve postural stability, and help regain balance
	Static standing with different arm positions (arms away from body, arms close to body, arms reaching forward, arms tossing a ball)	and physical function
Gait and balance training	Sitting to stand up	
	Sitting upright then bending down to pick up objects	

Walking with yaw head movement

Walking with pitch head movement

Tossing a ball above the eye level while

walking

Tandem walking on a level surface

Tandem walking on a foam surface

The difficulties of the tasks in each session are different according to each participant's balance performance (as measured by computerized dynamic posturography, CDP) or tolerance to vestibular stimulus. We intend to make the tasks progressively challenging. The approaches used to increase task challenge will be: (1) performing the exercises from a generally slow speed to an increased velocity; (2) change target distance (near to far) while performing VOR x1; (3) placing target in a distracting visual pattern; (4) performing the exercises with eyes open to with eyes shut; (5) with altered surface from solid surface to foam surface; (6) carrying out dual tasks such as doing math or talking on cell phone while walking.

The VR protocol consists of one office-based session each week by a skilled physiotherapist (Wu PX) at the clinic, and the other four days of home-based exercise. Compliance will be assessed during home exercise only. An exercise diary outlining the time and duration of each time exercise is required to be filled out every week. A video and booklet have been developed illustrating the program and are used as guides when participants carry out exercise at home. Figure 2 and figure 3 present the screenshots of the training video. During the first clinical visit sessions, the physiotherapist will provide adequate supervised vestibular rehabilitation for the patients to help them understand the goals of the program and ways to manage and progress themselves

1
2
3 independently. Patients are also instructed not to start any new physical activity during the study
4
5
6 period.

7
8 Participants in Group B (betahistine group) will be prescribed with betahistine 12mg
9
10 (manufactured by Wei Cai China Pharmaceutical Co., Ltd.), two tablets two times daily for 7 days.

11
12
13 Participants are asked not to take any other types of antivertiginous medicine in the course of the
14
15 study, or in case that scenario occurs, they should inform his/her ENT specialist. The pharmacy
16
17 department of the study hospital is responsible for dispensing betahistine to each participant.

18
19
20 There are 30 tablets in one prescription package. During the first follow-up visit (4-week post
21
22 randomization), participants are asked to bring their medicine package and the specialist will
23
24 count the tablets left, if the participant fully adheres to the protocol, then 2 tablets should be left.

25
26
27 Participants allocated in Group C (VR plus betahistine group) will receive a combination of VR
28
29 and betahistine protocol as described above.

30 31 32 **Adverse events**

33
34
35 Adverse events are rare while performing VR. However, patients are instructed to report any
36
37 complaints or symptoms during or after performing the exercises. The following symptoms are
38
39 considered as signs to stop or modify VR protocol: vomiting, nausea or muscle soreness, a feeling
40
41 of sharp or prolonged pain in the neck, arms or legs, a feeling of ear fullness, hearing loss or
42
43 tinnitus, double vision, fainting with experience of unconsciousness or blacking out. Adverse
44
45 events will be reported to Institute of Review board of Eye & ENT Hospital of Fudan University
46
47 within 48 hours.

48
49
50 The tolerability judgments for betahistine were reported as good.[34] Major possible side effects
51
52 include gastrointestinal system disturbances and headache.[35] In current study, participants are
53
54
55
56

1
2
3 encouraged to report spontaneously of any event after betahistine intake. The investigator will
4
5 routinely contact the participant once a week and ask if there are any unexpected symptoms
6
7 coming up. Any adverse events likely caused by betahistine during the trial will be recorded and
8
9 reported to the Adverse Drug Reaction (ADR) administration of Eye & ENT Hospital of Fudan
10
11 University within 48 hours.
12
13

14 15 **Withdrawal/ retention of participants**

16
17 Participation is voluntary in this study and the participants have the right to withdraw at any time.
18
19 However, we will use approaches as recommended by Dziura et al.[36] to improve adherence to
20
21 the intervention protocols and minimize attrition rates. These include data collection not requiring
22
23 clinical appointments, a reimbursement mechanism for extra auxiliary examination fees that
24
25 encourages study completion, and the provision of weekly phone-call contact during the trial. Any
26
27 concerns, such as unexpected symptoms, as well as logistic issues such as travelling to clinic or
28
29 parking issue will be evaluated during each telephone consultation. In rare cases, participants may
30
31 be withdrawn owing to unforeseen circumstances. Every reason for withdrawal will be recorded.
32
33
34
35
36

37 38 **Outcome measures**

39
40 Evaluating therapy success in patients suffering from vestibular disorder is often difficult due to
41
42 the complexity of this condition and the lack of specific apparatus-based parameters. Various
43
44 measurements have been utilized; however, no consensus was reached as to what aspects should
45
46 be addressed. An international group of investigators and health care providers developed a core
47
48 set, based on the International Classification of Functioning, Disability and Health (ICF)
49
50 framework, illustrating key aspects of functioning that should be measured when assessing
51
52 patients with vertigo, dizziness, and imbalance.[37] Of which, two main domains are included: (1)
53
54
55
56
57
58
59
60

1
2
3 body function and structure; (2) activity and participation. Recently published evidence-based
4
5
6 clinical practice guideline made recommendations for specific rehabilitation outcome assessment
7
8
9 by using recommended measures across the ICF domains.[26] In current study, both ICF-based
10
11 activity and participation aspect and apparatus-based measures will be included to capture the
12
13 whole picture of effectiveness of VR on managing RD after successful repositioning in BPPV
14
15
16 patients.

17 18 **Primary outcomes**

19
20 Primary outcomes are focused on patients' daily functional aspects and balance ability, which
21
22 include:

23
24
25 1. Participant's activity and participation, quantified by Vestibular Activities and Participation
26
27 (VAP) measure. The VAP is a 34-item self-report questionnaire based on ICF framework to
28
29 evaluate the effect of dizziness and/or balance problem on the ability to perform activity and
30
31 participation tasks.[38] The difficulty of each task is rated without assistance of other persons.
32
33 Each item of the VAP is set as a five-point scale indicating the level of difficulty; 0 refers to none
34
35 difficulty and 4 represents unable to do. Total score is obtained by calculating the average item
36
37 scores after excluding the "not applicable" responses. Previous study established cross-cultural
38
39 validity of VAP.[39] We recently have completed the translation and validation work of Chinese
40
41 version of VAP.
42
43
44
45

46
47 2. Balance function, measured by computerized dynamic posturography (CDP, Equitest,
48
49 NeuroCom International, Inc.). The Sensory Organization Test (SOT) of CDP evaluates the ability
50
51 of subjects to utilize vision, vestibular and somatosensory for maintaining their balance.[40] Six
52
53 increasingly challenging conditions (from SOT 1 through SOT6) that disrupt portions of balance
54
55
56

1
2
3 sensory input or visual surrounding are carried out to fulfill balance evaluation. An Equilibrium
4
5
6 Score (ES) for each condition is calculated by comparing the angular difference between the
7
8 subject's calculated maximum and minimum sagittal plane body sway to a theoretical maximum
9
10 displacement (12.5°). In terms of overall performance, a Composite Score (CS) is given as an
11
12 estimate of postural stability, a CS score near 100% indicates little sway, while scores approaching
13
14 0% indicate evidenced instability or fall. Both ES in each test condition from SOT 1 to SOT 6 and
15
16 the CS will be used for analysis in this study. The values are considered as abnormal when the
17
18 score is lower than the age-specific norm data.
19
20
21

22 23 ***Secondary outcomes***

24
25 Secondary outcomes include quality of life, recovery of otolith dysfunction, and duration of
26
27 symptoms.
28
29

30
31 1. Quality of life measured by DHI. DHI has been widely used as a reliable tool for evaluating the
32
33 self-perceived handicap effects imposed by vestibular system disease and has been translated and
34
35 standardized for the Chinese by Ding et al. [41] The DHI consists of 25 self-assessment items
36
37 which can be broken down into three subscales: physical, emotional, and functional. Total scores
38
39 of DHI range from 0 to 100 with increasing scores indicating greater perception of handicap
40
41 because of dizziness. It has been widely used as a reliable and valid tool for assessing the harmful
42
43 effects of dizziness on QoL of patients including BPPV.[42]
44
45
46

47
48 2. Otolith function, analyzed by Vestibular Evoked Myogenic Potentials (VEMPs). VEMPs is now
49
50 established as clinical test of otolith function. Cervical VEMP (cVEMP) is used to assess inferior
51
52 nerve otolith function (test mainly saccular function) and ocular VEMP (oVEMP) is believed to
53
54 exam superior nerve otolith function (test mainly utricular function). Previous studies[43,
55
56
57
58
59

1
2
3 44]identified that, in patients with BPPV underwent successful CRP, the occurrence of residual
4
5 symptoms was correlated to the abnormalities of oVEMP, suggesting that utricular dysfunction is
6
7 responsible for RD presence. Controversially, another study found that BPPV patients with
8
9 saccular dysfunction were more than those with utricular dysfunction[42]. Therefore, in present
10
11 study, both cVEMP and oVEMP will be recorded by using Bio-Logic Navigator Pro 9.0 (Natus
12
13 Medical Inc., San Carlos, USA) system. The procedure will be performed in a sound-proof room.
14
15 The methodology is reported in detail elsewhere.[45] Otolith dysfunction in our patients is defined
16
17 as the lack of unilateral responses in cVEMP or oVEMP.
18
19
20
21

22
23 3. Duration of symptoms reported by patients. During the trial period, a researcher contacts the
24
25 participants once a week to probe how many days do they experience symptoms in the previous
26
27 week. By the end of the study, the reported symptoms' day of each week will be added together
28
29 representing the whole duration of symptoms.
30
31

32 **Timepoint of outcome measures**

33
34 Outcome measures are applied at baseline and at three follow-ups. Baseline assessments occur on
35
36 the second day following successful CRP. Participants will repeat the same battery of tests
37
38 conducted at baseline and 4 weeks, 8 weeks and 12 weeks post allocation, with the exception of
39
40 CDP and VEMPs, which will only be repeated when the previous exam shows abnormal.
41
42
43

44
45 Schedule of enrollment, interventions and outcome assessments are presented in table2.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 Schedule of enrollment, interventions and outcome assessments

	Study period						
	Screening and eligibility	Allocation	Post allocation				Close-out
Timepoint	-T1	T0	T1	T2	T3	T4	
(D=day, W=week)		D2	D2-8	W4	W8	W12	
Eligibility screen	✓	✓					
Medical history reviewing	✓						
Physical and VNG examination	✓						
HADS	✓						
Informed consent	✓						
Allocation		✓					
Interventions							
VR (group A)			←→				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Betahistine (group B)			✓				
VR plus Betahistine (group C)			↔				
Assessments							
Outcome variables							
VAP		✓		✓	✓	✓	
CDP		✓		✓/#	✓/#	✓/#	
DHI		✓		✓	✓	✓	
oVEMP		✓		✓/#	✓/#	✓/#	
cVEMP		✓		✓/#	✓/#	✓/#	
Symptom duration		✓		✓	✓	✓	✓

Abbreviations. VNG, videonystagmography; HADS, Hospital Anxiety and Depression Scale; VR, vestibular rehabilitation; VAP, the Vestibular Activities and Participation measure; CDP, computerized dynamic posturography; DHI, Dizziness Handicap Inventory; VEMP, Vestibular Evoked Myogenic Potential.

Statistical analysis

Sample size calculation

The study sample size was based on one of the primary outcomes--- VAP measure, which is a useful clinical tool to assess a patient's limitation in activities and participation due to vertigo, dizziness, and unsteadiness. The validation study of VAP in patients who complained about dizziness or imbalance showed the minimum detectable change (MDC) for the VAP was 0.58, with a standard error of 0.21[39]. In this study, a 0.6 difference of VAP score is considered clinically meaningful. Thus, to detect an MDC of 0.6 for the VAP with 80% power (alpha level of 0.05, two-sided test), 55 per group will be required. Although there are three groups in this study, controlling for type 1 error rate is not needed because our hypotheses are: (1) VR will be better than betahistine (Group A versus Group B) and (2) VR will be non-inferior to VR plus betahistine (Group A versus Group C); therefore, only two comparisons will be executed. Allowing a 20% loss to follow-up, a total sample of 183 (61 per group) will be required for the current study.

Data Analysis

Statistical analyses will be completed using IBM SPSS Statistics for Windows (SPSS V.22.0) and the level of significance will be set at $p < 0.05$. Firstly, descriptive analysis will be conducted to determine outliers and distributions of the data. Then, the intervention group and control group will be analyzed for baseline comparability with respect to the baseline variables. Analysis of the outcome measures will be based on the conservative intention-to-treat (ITT) approach; moreover, as a secondary analysis, a per protocol analysis will also be performed. Drop-out / attrition is anticipated. We will examine the structure and pattern of missing data and, if appropriate, multiple imputation methods will be used in both ITT and the per-protocol analyses.

1
2
3
4 The main analysis of change in the primary outcomes (VAP score and SOT composite) will use
5
6 mixed-model with repeated measures (MMRM) models, with fixed effects for group and time and
7
8 a random effect for subject. Mathematical transformation or categorization of raw scores will be
9
10 undertaken to meet distributional assumptions that required in MMRM models. Models will adjust
11
12 for age, gender and other baseline potential confounders. Secondary outcomes include both
13
14 continuous data (DHI score, duration of symptoms) and dichotomous data (otolith function,
15
16 defined as normal or abnormal). Analysis of secondary outcomes will be conducted using mixed
17
18 model with repeated measures for continuous outcomes or logistic regression for dichotomous
19
20 data, again controlling for baseline potential confounders. Statistical analysis will be carried out by
21
22 a statistician from Fudan University Medical School, who is blinded to group allocation and study
23
24 hypothesis. To achieve that blinding, all participants are anonymized and study arms are coded as
25
26 A, B, C.
27
28
29
30
31

32 **Trail status and recruitment**

33
34 Protocol V.2.0, 10 August, 2018. Planned date of first enrolment is September 1, 2018. The
35
36 estimated time required for recruitment is 15 months. The total duration of this study is expected
37
38 to be 23 months, including statistical analysis and study results drafting.
39
40
41

42 **Data management**

43
44 Data Safety and Monitoring Board (DSMD) has already been set up. DSMD will monitor
45
46 day-to-day running of the trial, review the accumulation data, check database integrity, and be
47
48 responsible for carry out interim analyses. DSMD consists of five persons: a chair, a statistician, a
49
50 methodologist experienced in research with BPPV, a clinical expert, and a patient representative.
51
52
53

54
55 All members are independent from the study sponsor and report no competing interest. The
56
57
58
59

1
2
3 DSMD meets approximately every month from the start of the trial. Trial sponsor compensate
4
5
6 DSMD members for their time and effort, similar to the compensation provided to other trial
7
8 support personnel.
9

10
11 For data collection, an electronic case report form (CRF) has been designed to record all the data
12
13 from the baseline and the three follow-ups during the trial. Electronic data are stored on a public
14
15 platform at www.medresman.org sponsored by China clinical trial registry center. The database
16
17 uses standard techniques to provide security. Access to database is controlled by user names and
18
19 encrypted passwords. Individual participant data (IPD) will be made public in 6 months after the
20
21 completion of the study through the IPD sharing platform.
22
23
24

25 **Patient and public involvement**

26
27 Patients and the public were not involved in the design of this study. However, we have consulted
28
29 with a patient representative about his views on how best to involve patients throughout the
30
31 proposed project. His views have been incorporated in our revised protocol. Patients and the
32
33 public will be informed of the study results via peer-reviewed journals or academic conference.
34
35
36

37 **Dissemination of the study findings**

38
39 We plan to publish the study findings in peer-reviewed academic journals. We also intend to
40
41 deliver presentation of this study at local, national and international conferences where possible.
42
43 Furthermore, we will draft a summary of the study results on website of Eye & ENT hospital that
44
45 can be accessed by all trial participants as well as relevant interest groups.
46
47
48

49 **Competing interests**

50
51 No competing interests exist.
52
53

54 **Funding**

1
2
3 This study was supported by Science and Technology Commission of Shanghai Municipality
4
5
6 (grant number.184119551900) and the Department of Otorhinolaryngology at Eye & ENT
7
8 Hospital of Fudan University.
9

10 **Ethics approval**

11
12
13 Institute Review Board of Eye & ENT Hospital of Fudan University (reference number.2017046).
14

15 **References**

- 16
17
18 1. Von BM, Radtke A, Lezius F, *et al.* Epidemiology of benign paroxysmal positional vertigo: a
19
20 population based study. *J Neurol Neurosurg Psychiatry* 2007;78:710-15.
21
22
23 2. Kim JS, Zee DS. Clinical practice. Benign paroxysmal positional vertigo. *New Engl J Med*
24
25 2014;370:1138-47.
26
27
28 3. Schuknecht HF, Ruby RR. Cupulolithiasis. *Adv Otorhinolaryngol* 1973; 20:434-43.
29
30
31 4. Epley JM. The Canalith Repositioning Procedure: For Treatment of Benign Paroxysmal
32
33 Positional Vertigo. *Otolaryngol Head Neck Surg* 1992; 107:399-404.
34
35
36 5. Brandt T, Steddin S. Current view of the mechanism of benign paroxysmal positioning
37
38 vertigo: cupulolithiasis or canalolithiasis? *J Vestib Res*1993; 3:373-82.
39
40
41 6. Inagaki T, Suzuki M, Otsuka K, *et al.* Model experiments of BPPV using isolated utricle and
42
43 posterior semicircular canal. *Auris Nasus Larynx* 2006; 33:129-34.
44
45
46 7. Bhattacharyya N, Gubbels SP, Schwartz SR, *et al.* Clinical practice guideline: benign
47
48 paroxysmal positional vertigo (Update). *Otolaryngol Head Neck Surg* 2017;156(3S):S1-47.
49
50
51 8. Martellucci S, Pagliuca G, de Vincentiis M, *et al.* Features of Residual Dizziness after
52
53 Canalith Repositioning Procedures for Benign Paroxysmal Positional Vertigo. *Otolaryngol Head*
54
55 *Neck Surg* 2016; 49:74-78.
56

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
9. Swain SK BI, MC S. Role of Ginkgo biloba for controlling residual dizziness after successful treatment of benign paroxysmal positional vertigo: Our experiences at a tertiary care teaching hospital of Eastern India. *Int J health Allied Sci* 2018; 7:196-200.
10. Seok JI, MD, Lee HM, *et al.* Residual dizziness after successful repositioning treatment in patients with benign paroxysmal positional vertigo. *J Clin Neurol* 2008; 3:107-16.
11. Giommetti G, Lapenna R, Panichi R, *et al.* Dizziness after Successful Repositioning Maneuver for Idiopathic Benign Paroxysmal Positional Vertigo. *Audiol Res* 2017;178:31-7.
12. Vaduva C, Estéban-Sánchez J, Sanz-Fernández R, *et al.* Prevalence and management of post-BPPV residual symptoms. *Eur Arch Otorhinolaryngol* 2018; 275:1429–1437
13. Lopez-Escamez JA, Gamiz MJ, Fernandez-Perez A, *et al.* Long-term outcome and health-related quality of life in benign paroxysmal positional vertigo. *Eur Arch Otorhinolaryngol* 2005; 262:507-11.
14. Korres S, Balatsouras DG, Ferekidis E. Prognosis of patients with benign paroxysmal positional vertigo treated with repositioning manoeuvres. *J Laryngol Otol* 2006; 120:528-33.
15. Faralli M, Lapenna R, Giommetti G, *et al.* Residual dizziness after the first BPPV episode: role of otolithic function and of a delayed diagnosis. *Eur Arch Otorhinolaryngol* 2016; 273(10):1-9.
16. Seo T, Shiraishi K, Kobayashi T, *et al.* Residual dizziness after successful treatment of idiopathic benign paroxysmal positional vertigo originates from persistent utricular dysfunction. *Acta Otolaryngol* 2017; 137:1-4.
17. Kim HA, Lee H. Autonomic dysfunction as a possible cause of residual dizziness after successful treatment in benign paroxysmal positional vertigo. *Clin Neurophysiol* 2014;

1
2
3 125:608-14.
4

5
6 18. Staab JP, Eckhardtthenn A, Horii A, *et al.* Diagnostic criteria for persistent
7
8 postural-perceptual dizziness (PPPD): Consensus document of the committee for the
9
10 Classification of Vestibular Disorders of the Bárány Society. *J Vestib Res* 2017; 27:1-18.
11
12

13 19. Rubenstein L Z, Kenny R A, Eccles M, *et al.* Preventing falls in older people: new advances
14
15 and the development of clinical practice guidelines. *J R Coll Physicians of Edinb*
16
17 2003;33:262-272.
18
19

20 20. Abou-Elew MH, Shabana MI, Selim MH, *et al.* Residual postural instability in benign
21
22 paroxysmal positional vertigo. *J Audiol Med* 2011; 9:8-15.
23
24

25 21. Teggi R, Quagliari S, Gatti O, *et al.* Residual Dizziness after Successful Repositioning
26
27 Maneuvers for Idiopathic Benign Paroxysmal Positional Vertigo. *Eur Arch Otorhinolaryngol* 2011;
28
29 268:507-11.
30
31

32 22. Vugt VAV, Horst HEVD, Payne RA, *et al.* Chronic vertigo: treat with exercise, not drugs.
33
34 *BMJ.* 2017;358: j3727.
35
36

37 23. Guneri EA, Kustutan O. The effects of betahistine in addition to epley maneuver in posterior
38
39 canal benign paroxysmal positional vertigo. *Otolaryngol Head Neck Surg* 2012;146(1):104-08.
40
41

42 24. Acar B, Karasen RM, Buran Y. Efficacy of medical therapy in the prevention of residual
43
44 dizziness after successful repositioning maneuvers for Benign Paroxysmal Positional Vertigo
45
46 (BPPV). *B-ENT* 2015; 11:117-21.
47
48

49 25. Hillier SL, McDonnell M. Vestibular rehabilitation for unilateral peripheral vestibular
50
51 dysfunction. *Cochrane Db Syst Rev* 2011; 2: CD005397
52
53

54 26. Hall CD, Herdman SJ, Whitney SL, *et al.* Vestibular Rehabilitation for Peripheral Vestibular
55
56

1
2
3 Hypofunction: An Evidence-Based Clinical Practice Guideline: from the American physical
4 therapy association neurology section. *J Neurol Phys Ther* 2016; 40:124-55.
5
6

7
8 27. Shepard NT, Telian SA, Smithwheelock M. Habituation and balance retraining therapy: A
9 retrospective review. *Neurol Clin* 1990; 8:459-75.
10
11

12
13 28. Herdman SJ, Blatt PJ, Schubert MC. Vestibular rehabilitation of patients with vestibular
14 hypofunction or with benign paroxysmal positional vertigo. *Curr Opin Neurol* 2000; 13:39-43.
15
16

17
18 29. Bhattacharyya N, Gubbels SP, Schwartz SR, *et al.* Clinical practice guideline: benign
19 paroxysmal positional vertigo. *Otolaryngol Head Neck Surg* 2017;156: S1-47.
20
21

22
23 30. Hillier SL, McDonnell M. Vestibular rehabilitation for unilateral peripheral vestibular
24 dysfunction. *Clin Otolaryngol* 2011; 36:248-49.
25
26

27
28 31. Bressi F, Vella P, Casale M, *et al.* Vestibular rehabilitation in benign paroxysmal positional
29 vertigo: Reality or fiction? *Int J Immunopathol Pharmacol* 2017; 30:113-22.
30
31

32
33 32. Chang WC, Yang YR, Hsu LC, *et al.* Balance improvement in patients with benign
34 paroxysmal positional vertigo. *Clin Rehabil* 2008; 22:338-47.
35
36

37
38 33. Ribeiro KM, Freitas RV, Ferreira LM, *et al.* Effects of balance Vestibular Rehabilitation
39 Therapy in elderly with Benign Paroxysmal Positional Vertigo: a randomized controlled trial.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

34. Otto V, Fischer B, Schwarz M, *et al.* Treatment of vertebrobasilar insufficiency--associated
vertigo with a fixed combination of cinnarizine and dimenhydrinate. *Int Tinnitus J* 2008; 14:57-67.

35. Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. *Cochrane Db Syst
Rev.* 2016;6: D10696.

36. Dziura JD, Post LA, Zhao Q, *et al.* Strategies for Dealing with Missing Data in Clinical

- 1
2
3
4 Trials: From Design to Analysis. *Yale J Biol Med*. 2013; 86:343-58.
5
6 37. Grill E, Bronstein A, Furman J, *et al*. International Classification of Functioning, Disability
7 and Health (ICF) Core Set for patients with vertigo, dizziness and balance disorders. *J Vestibul*
8
9 *Res-Equil*. 2012; 22:261-71.
10
11
12
13 38. Alghwiri AA, Whitney SL, Baker CE, *et al*. The development and validation of the vestibular
14 activities and participation measure. *Arch Phys Med Rehabil* 2012; 93:1822-31.
15
16
17
18 39. Mueller M, Whitney SL, Alghwiri A, *et al*. Subscales of the Vestibular Activities and
19 Participation questionnaire could be applied across cultures. *J Clin Epidemiol* 2015;68: 211-19.
20
21
22
23 40. Nashner, LM. *Computerized dynamic posturography*. In: Jacobson GP SNE, editor *Balance*
24 *Function Assessment and Management*. San Diego: Plural Publishing; 2016.
25
26
27
28 41. Ding L, Liu C, Wang JX. An Evaluaiton of the Dizziness Handicap Inventory (Chinese
29 version). *Chinese Journal of Otolology*. 2013;11:228-30. In Chinese
30
31
32
33 42. Hoseinabadi R, Pournakht A, Yazdani N, *et al*. The effects of abnormality of cVEMP and
34 oVEMP on rehabilitation outcomes in patients with idiopathic benign paroxysmal positional
35 vertigo. *Eur Arch Otorhinolaryngol*. 2016; 273:643-48.
36
37
38
39
40 43. Tian Yongsheng, Zhang Yan, Ma Rong, *et al*. Features of vestibular evoked myogenic
41 potential in patients with residual dizziness after canalith repositioning procedures for benign
42 paroxysmal positional vertigo. *J Clin Otorhinolaryngol Head Neck Surg (China)* 2018; 32:845-49.
43
44
45
46
47 In Chinese
48
49
50 44. Seo T, Shiraishi K, Kobayashi T, *et al*. Residual dizziness after successful treatment of
51 idiopathic benign paroxysmal positional vertigo originates from persistent utricular dysfunction.
52
53
54
55 *Acta Otolaryngol*. 2017; 137:1-4.
56
57
58
59
60

1
2
3
4 45. Zhou YJ, Wu YZ, Cong N, *et al.* Contrasting results of tests of peripheral vestibular function
5
6 in patients with bilateral large vestibular aqueduct syndrome. *Clin Neurophysiol.* 2017; 128:1513-
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1 Study flow chart.

Figure 2 Screenshot of head movement exercises in the training video.

Figure 3 Screenshot of gait exercise in the training video.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



223x238mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 2 Screenshot of head movement exercises in the training video

285x160mm (300 x 300 DPI)




Figure 2 Screenshot of gait exercises in the training video

528x297mm (96 x 96 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Page Number on which item is reported
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	3	Date and version identifier	22
Funding	4	Sources and types of financial, material, and other support	23
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	In title page
	5b	Name and contact information for the trial sponsor	In title page
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	In title page
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	-
Introduction			

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	4-8
	6b	Explanation for choice of comparators	-
Objectives	7	Specific objectives or hypotheses	8
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	8,11
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	8,9
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	11-14
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	15
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	15
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	14,15
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	16-18

Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	19-20
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	21
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	15
Methods: Assignment of interventions (for controlled trials)			
Allocation:			
Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	11
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	11
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	11
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	11
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	-
Methods: Data collection, management, and analysis			

1 2 3 4 5 6 7 8 9 10	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	16-18
11 12 13 14 15 16		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	15
17 18 19 20 21 22 23 24	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	22
25 26 27 28 29	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	21-22
30 31 32		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	21-22
33 34 35 36 37 38		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	22
39	Methods: Monitoring			
40 41 42 43 44 45 46 47 48	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	22
49 50 51 52 53 54 55 56 57 58 59 60		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	22,23

Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	14,15
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	14-
Ethics and dissemination			
Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	25
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	-
Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	10
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	-
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	10
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	23
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	23
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	Informed consent (annex)
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	23

	31b	Authorship eligibility guidelines and any intended use of professional writers	-
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	-
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	annex
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	-

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

The effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning maneuvers in patients with benign paroxysmal positional vertigo : protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026711.R1
Article Type:	Protocol
Date Submitted by the Author:	07-Jan-2019
Complete List of Authors:	wu, Peixia; Eye & ENT Hospital of Fudan University Cao, Wenzhu; Eye and ENT Hospital of Fudan University, intensive care unit Hu, Yan; School of Nursing, Fudan University Li, Huawei; Eye & ENT Hospital of Fudan University, Department of Otorhinolaryngology
Primary Subject Heading:	Ear, nose and throat/otolaryngology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology
Keywords:	benign paroxysmal positional vertigo, vestibular rehabilitation, dizziness, randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4 **The effects of vestibular rehabilitation, with or without betahistine, on managing residual**
5
6 **dizziness after successful repositioning maneuvers in patients with benign paroxysmal**
7
8 **positional vertigo : protocol for a randomized controlled trial**
9
10

11 Wu Peixia,¹ Cao Wenzhu,² Hu Yan,³ Li Huawei⁴

12
13
14 1. Department of operation room, Eye and ENT Hospital of Fudan University, Shanghai, China

15
16
17 2. Intensive care unit, Eye and ENT Hospital of Fudan University, Shanghai, China

18
19
20 3. School of Nursing, Fudan University, Shanghai, China

21
22
23 4. Department of Otorhinolaryngology, Eye and ENT Hospital of Fudan University, Shanghai,
24
25 China

26
27 Co-Corresponding author: Dr. Li Huawei, Head of Department of Otorhinolaryngology, Eye and
28
29 ENT Hospital of Fudan University, No.83 Fenyang Road, Shanghai, 200031, China; Tel: 86-21-
30
31 64377134-669; E-mail: hwli@shmu.edu.cn

32
33
34
35 Co-Corresponding author: Dr. Yan Hu, President of School of Nursing, Fudan University, No.305
36
37 Fenling Road, Shanghai, 200031, China; E-mail: fudanhuyan@163.com

38
39
40 **Contributors** All authors have made an intellectual contribution to this protocol. Li Huawei is the
41
42 principal investigator of the trial, with full responsibility for the project. Wu PX, Cao WZ and Hu
43
44 Yan conceived the design, developed the protocol and wrote the first draft of this manuscript. Li
45
46 Huawei and Hu Yan revised and approved the final version of the study protocol and the final
47
48 manuscript. Li Huawei and Hu Yan are co-corresponding authors whom contributed this paper
49
50
51
52
53
54
55
56
57
58
59
60
equally.

Abstract

Introduction

Benign paroxysmal positional vertigo (BPPV) is recognized as the leading cause of periphery vertigo in adults. Canalith repositioning procedure (CRP) can effectively treat BPPV. However, a certain group of patients experience residual dizziness (RD) even after successful CRP, bringing a significantly negative impact on their daily function and quality of life. Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness and has been applied in patients with different vestibular disorders. However, the effectiveness of VR specifically targeted RD post BPPV is unknown. This study aims to investigate the effectiveness of VR, compared with betahistine or VR plus betahistine, in patients experiencing RD after successful CRP.

Methods and analysis

A randomized single-blinded controlled trial will be carried out to determine the effectiveness of VR, compared with betahistine or VR plus betahistine, in mitigating RD and improving balance function. Patients with BPPV after successful CRP and complain of experiencing RD will be recruited. Participants will be randomized into one of three groups to receive VR or betahistine or VR plus betahistine. There will be 61 participants in each group. Primary outcomes are changes of patients' daily function measured by Vestibular Activities and Participation (VAP) questionnaire and balance ability assessed by computerized dynamic posturography (CDP). Secondary outcomes will assess dizziness-related handicap, otolith function, and duration of RD symptoms.

Outcome measures will be taken at baseline, 2-week, 4-week and 8-week post randomization. This study has the potential to arrive at stopping unnecessary anti-vertigo drugs prescriptions and may lead to the consensus of using VR as the first-line treatment for RD in patients with BPPV.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ethics and dissemination

This trial received ethics approval from Institute Review Board of Eye & ENT Hospital of Fudan University (2017046). Study results will be disseminated through peer-reviewed journals and conferences.

ClinicalTrials.gov identifier: NCT03624283

For peer review only

Strengths and limitations of this study

► To our knowledge, this is the first randomized controlled trial evaluating the effects of vestibular rehabilitation, compared with betahistine or VR in addition to betahistine, on managing residual dizziness after successful CRP in patients with BPPV.

► Both subjective and objective outcome measures are comprehensively assessed with reasonable long follow-up time. In Particular, patients' activities and participation aspect based on International Classification of Functioning, Disability and Health (ICF) framework are evaluated. Such a trial will be able to fully reflect the efficacy of proposed intervention.

► For practical reason, there is no sham or placebo or no treatment as comparison group in this study; therefore, the study cannot tell whether participants improve simultaneously or how the three interventions may work in different ways to change outcomes.

INTRODUCTION

Benign paroxysmal positional vertigo (BPPV) is the leading cause of peripheral vertigo, with a prevalence from 10.7 to 64 per 100,000 populations and a lifetime prevalence of 2.4%. [1] The onset time is most commonly between the fifth and seventh decade of life, but BPPV could occur at any age. [2] Two theories --- cupulolithiasis [3] and canalithiasis [4], are among the most widely accepted theories that elucidate the pathophysiology of BPPV. Canalithiasis has gained wider acceptance among the scientific field due to the symptoms being better explained. [5] According to the canalolithiasis hypothesis, BPPV is caused by free otoconia dislodged from the utricular macula and entering into the semicircular canal, which therefore provokes an inappropriate flow of endolymph whenever the head is rotated in the plane of the affected canal. [4] Although any of the three semicircular canals can be affected, the posterior semicircular canal BPPV is the most common, followed by horizontal canal BPPV. Treatment of BPPV is based on the performance of canalith repositioning procedure (CRP), with the aim of repositioning the displaced particles from the affected canal to their original location. [6] CRP has long emerged as a mainstay of therapy and now is well established as the gold treatment for BPPV. [7] Posterior canal BPPV can be treated by performing Epley's maneuver or Semont's liberatory maneuver. For horizontal canal BPPV, Barbecue rotation or Gufoni's maneuvers have been shown effective.

Despite the fact that CRP can provide rapid relief of vertigo sensation in BPPV patients, residual symptoms may remain even after disappearance of typical vertigo and nystagmus following a successful CRP. These residual symptoms, also referred as residual dizziness (RD), imply a non-specific sensation of unsteadiness, lightheadedness, disorientation, foginess or drowsiness. [8]

The reported incidence of RD ranges from 29.6% to 76.9% and the duration of RD can range from

1
2
3
4 a few days to several months.[8-12] Several Authors reported that RD symptoms may persist up to
5
6 more than 3 months [13, 14], bringing adverse physical and psychological consequences to these
7
8 patients.
9

10
11 Different pathophysiological mechanisms have been proposed to explain the presence of RD but
12
13 the real cause remains unknown. Previously reported possible explanations included: (1) the
14
15 persistence of debris in the canal being insufficient to provoke detectable positional nystagmus or
16
17 vertigo;[11] (2) otolith dysfunction;[15, 16] (3) coexistent vestibular disease that lead to
18
19 incomplete central adaptation; (4) potential autonomic dysfunction such as orthostatic
20
21 hypotension;[17] (5) persistent postural-perceptual dizziness (PPPD).[18]
22
23
24
25

26
27 Dizziness increases the risk of falls or fear of falling, disturbs daily life, and results in restriction
28
29 of social activities. As a result, many people tend to avoid activities, limit their movement, and
30
31 avoid specific circumstances because of fear of provoking dizziness and unanticipated
32
33 unsteadiness attacks.[19] It is not surprised that increased postural instability was documented in
34
35 patients who experiencing RD[20, 21]. Given that high prevalence of RD after successful
36
37 repositioning and its negative impact on patient recovery, this impairment should be managed
38
39 properly.
40
41
42
43
44

45
46 To date, there is no agreement on how to effectively manage RD after successful CRP in patients
47
48 with BPPV. Betahistine is the most widely used medication to ameliorate dizziness, due to its
49
50 effects of increasing labyrinthine microcirculation, suppressing the increased neuronal activity in
51
52 vestibular receptor cells, afferent neurons, and vestibular nuclei.[11, 22] However, conflicting data
53
54 exists regarding the efficacy of betahistine for preventing or treating RD. Guneri et al[23]
55
56 evaluated the efficacy of betahistine in reducing symptoms after Epley maneuver for posterior
57
58
59
60

1
2
3
4 canal BPPV, they found 48 mg of betahistine daily intake demonstrated more effective results
5
6 than Epley maneuver alone or combined with placebo in improving symptoms assessed by four
7
8 different vertigo symptoms scales. On the contrary, Acar et al [24] carried out a randomized
9
10 controlled clinical trial to investigate the efficacy of betahistine, compared with a no medication
11
12 group, for the treatment of RD after successful CRP. After 3 and 5 days of treatment, the mean
13
14 DHI (Dizziness Handicap Inventory) scores of the groups receiving medication did not differ from
15
16 the mean DHI score of the control group, indicating betahistine did not produce any more
17
18 alleviation of RD than no treatment. However, both studies have unclear randomization sequence
19
20 generation, allocation concealment and only included subjective outcomes, suggesting more
21
22 rigorous methodology of clinical trials that including comprehensive outcomes assessment are
23
24 warranted.

25
26 Recently, non-pharmacological interventions, such as vestibular rehabilitation (VR), are
27
28 recommended as the first line of treatment for chronic vertigo.[22] VR, which has been available
29
30 since 1940s, is an exercise-based treatment consisting of varied eye, head, and body movements
31
32 designed to stimulate the vestibular system and optimize vestibular compensation.[25] Current VR
33
34 approach typically includes a combination of three different exercise components to address the
35
36 impairments or functional limitations identified during evaluation: (1) gaze stability exercises, (2)
37
38 habituation exercises, including optokinetic exercises, (3) balance and gait training in different
39
40 conditions.[26] The aim of VR is to improve the visual-vestibular interaction and increase balance
41
42 ability. It is also evidenced to contribute to an improvement in daily function and a reduction of
43
44 symptoms of dizziness.[26] The mechanism for its effectiveness is thought to rely on the
45
46 following three aspects: (1) compensation/habituation, which is a central process, refers to that
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 repeated exposure to a provocative stimulus will result in a reduction in the symptomatic response
5
6 to that treatment[27]; (2) adaptation, which is the recovery of the dynamic vestibulo-ocular
7
8 responses due to the ability of the vestibular system to make long-term changes in the neuronal
9
10 response to input; and (3) substitution, which is the use of other strategies to replace the lost
11
12 function.[28]
13
14

15
16 An updated evidence-based clinical guideline by American Academy of Otolaryngology-Head and
17
18 Neck Surgery Foundation (AAO-HSNF) points out that the clinician should offer VR in treatment
19
20 of BPPV, stating that although movement/ habituation-based VR should not be first-line treatment
21
22 modality for BPPV, it is indicated for patients who have persistent disability following CRP.[29]
23
24 VR is particularly indicated in subjects with additional impairments, such as nonspecific dizziness
25
26 and those patients with heightened fall risk.[7] A Cochrane review [30] has been undertaken to
27
28 assess the effectiveness of VR in people with symptomatic unilateral peripheral vestibular
29
30 dysfunction (UPVD) which included eight studies investigated VR in BPPV specifically,
31
32 supporting the thought that the primary intervention for BPPV should be CRP that directly treat
33
34 the condition, but movement/habituation-based VR will further aid and benefit long-term
35
36 functional recovery. A more recent review by Bressi et al.[31] proposes that a hierarchy of
37
38 interventions should be offered to people with BPPV, starting with CRP followed by post-
39
40 treatment exercises. They also indicate that CRP and VR seem to have a synergic effect in patients
41
42 with BPPV.[31]
43
44
45
46
47
48
49
50
51

52
53 While previous studies shed light on the great beneficial of VR in BPPV patients, to date, no
54
55 randomized clinical trial has been conducted to specifically investigate VR, with or without
56
57 betahistine, in dealing with RD following CRP in patients with BPPV. This study has been
58
59
60

1
2
3
4 designed with the broad aim of verifying VR as the first-line option in treating RD, which is
5
6 conformed to the current recommendations for best clinical practice with respect to the
7
8 implementation of VR for persons with impairments and functional limitations related to the
9
10 vestibular deficit.[26] Moreover, the present study has the potential to arrive at stopping
11
12 unnecessary anti-vertigo drugs prescriptions in BPPV patients.
13
14
15

16 17 **Aims of the study**

18
19 This study will investigate the effects of VR, compared with betahistine or VR plus betahistine, on
20
21 managing RD after successful CRP in patients with BPPV.
22
23

24 We hypothesize that participants in VR group, compared with participants in betahistine group,
25
26 will display fewer activities and participation restrictions and less balance inability. Moreover, we
27
28 expect that participants in VR group would experience shorter duration of RD, less dizziness-
29
30 related handicap and enhanced recovery of otolith dysfunction (if any).
31
32

33 We also hypothesize that the effects of VR alone will be non-inferior to a combination of VR and
34
35 betahistine, in terms of outcome measures mentioned above.
36
37

38 39 **METHODS AND ANALYSIS**

40 41 **Study design, setting, and participants**

42
43 This study is designed as a randomized controlled prospective single-blinded trial. Outcome
44
45 assessment will be conducted by two researchers who are blinded to group allocation.
46
47

48 The study setting is the largest ENT-specialized hospital in China. The hospital serves a
49
50 population of about 23 million of Shanghai. It also serves as a referral center accepting patients
51
52 from all over the country.
53
54
55

56 The eligibility criteria are as follows: (1) diagnosed as unilateral BPPV (unilateral posterior
57
58
59
60

1
2
3
4 semicircular canal BPPV or horizontal semicircular canal BPPV) according to the clinical practice
5
6 guideline by AAO-HNSF in 2017[29], (2) aged 18~80 years, (3) reporting residual symptoms
7
8 after successful repositioning maneuvers. Participants will be excluded if they are: (1) confirmed
9
10 as anterior semicircular canal BPPV or multicanal BPPV, (2) recurrent BPPV, (3) with coexisting
11
12 vestibular disorders, including Meniere disease, vestibular neuritis, labyrinthitis, and peripheral
13
14 vestibular loss, (4) with severe cervical spine disease, (5) with severe cardiovascular diseases, (6)
15
16 with known cerebral vascular disease like carotid stenosis, (7) pregnant/ lactating or planning to
17
18 become pregnant during the study period, (8) those who had taken vestibulosuppressant,
19
20 antihistamines, and/ or ototoxic medications in the previous 3 months.
21
22
23
24
25
26

27 **Procedure**

28
29
30 The study protocol was reviewed and approved by the Institutional Review Board of the Eye &
31
32 ENT Hospital of Fudan University (Reference Number:2017046). Patients who are suspected of
33
34 having BPPV and visit ENT specialist are possibly eligible for this study. They will undergo Dix–
35
36 Hallpike test, roll test, and anterior canal provoking test to confirm as suffering from solely
37
38 unilateral posterior canal or horizontal canal involved. After diagnosis by ENT specialist, posterior
39
40 canal BPPV will be treated using Epley’s maneuver or Semont’s liberatory maneuver, while
41
42 horizontal canal BPPV will be treated with Barbecue rotation maneuvers. The same
43
44
45
46
47
48 physiotherapist applies both testing procedure and CRP maneuver. CRP is repeated up to three
49
50
51 times during one day. After successful repositioning maneuver, patients are asked to complete a
52
53 DHI test. Patients who failed when up to three CRPs have been performed will not be included in
54
55
56 this study.

57
58 On the second day following successful CRP, a lead investigator will contact the patient by either
59
60

1
2
3
4 telephone or Wechat. Patients will be asked whether they are experiencing residual symptoms. If
5
6 yes, they will be initially screened through telephone interview and those who meet the inclusion
7
8 criteria will be invited to participate in the study. A face-to-face interview will be arranged for
9
10 patients who express an interest in the trial, and formal written consent will be obtained from
11
12 candidates who agree to participate. After obtaining written consent form, the principal
13
14 investigator (Li HW) will fully review the participant's medical history, execute physical
15
16 examination and perform videonystagmography (VNG) including caloric test, to rule out any
17
18 central nervous system pathologies or other vestibular diseases. Diagnostic test for BPPV will be
19
20 repeated to make sure findings are negative. Pure-tone audiometry and tympanometry will be
21
22 checked. Gait and balance will also be assessed (Romberg, sharpened Romberg). Whenever
23
24 necessary, imaging exam such as CT scan or MRI is supplemented to exclude cerebellar disorders.
25
26 The purpose of above-mentioned examinations is to confirm the diagnosis and validate the
27
28 homogeneity of all participants who take part in current study. After eligibility screenings,
29
30 participants then will be randomly allocated into one of three groups: participants in Group A will
31
32 perform VR exercises; Group B will be described with betahistine; and Group C will be offered
33
34 with both VR and betahistine. Outcome measures will be taken at baseline, two-week, four-week,
35
36 and eight-week post randomization. Outcome measurements will be executed by two independent
37
38 research staff, one is responsible for apparatus-based measures and another in charge of subjective
39
40 data collecting, both of whom are unaware of the treatment assignment until the end of the study.
41
42
43
44
45
46
47
48
49
50
51
52
53 See figure 1 for a study flow chart.
54
55

56 **Randomization and blinding**

57
58 Participants will be randomized into three groups of 61 each. The randomization process will be
59
60

1
2
3
4 carried out by an internet-based randomization tool provided by China clinical trial registration
5
6 center. The website is accessible to public via <http://www.medresman.org/login.aspx>. The
7
8 randomization sequence will be generated automatically when the administrator logs on the
9
10 website asking for the allocation number once an eligible patient is recruited. Participants will be
11
12 randomly allocated at a ratio of 1:1:1 with stratified by sex and age (≤ 60 years, >60 years). As the
13
14 randomization is on-line and automatic, neither the researchers nor the patients can manipulate
15
16 which treatment the patients are receiving, therefore to ensure group allocations are randomly
17
18 assigned.
19
20
21
22
23

24 Since VR is an operational intervention, it is not possible for either patients or the physiotherapists
25
26 and physicians to be blind to allocation. However, two independent research staff will contact
27
28 patients to collect both subjective and apparatus-based data. The statistician of our trial team will
29
30 remain blind until statistical analyses are complete.
31
32
33

34 35 **Interventions**

36
37 Following eligible screening, participants are randomly assigned to one of three intervention
38
39 groups.
40
41

42
43 Participants in Group A (VR group) will perform vestibular rehabilitation exercises twice a day,⁷
44
45 days per week, over a period of four weeks. The exercise protocol was developed based on clinical
46
47 experience and adapted from the previous studies.[32, 33] in which vestibular stimulated exercise
48
49 applied were shown to improve balance ability and functional performance among BPPV patients
50
51 who had undergone CRP. A dedicated physiotherapist (Wu PX) drafted the initial protocol. The
52
53 content was then reviewed by three experts with expertise in caring for patients with chronic
54
55 dizziness, and was piloted with two female and two male patients who have experienced RD post
56
57
58
59
60

BPPV. Participants reported no difficulties in practicing these exercises. The protocol primarily consists of three categories: oculomotor exercises, head movement exercises, gait and balance training, which is described in table 1.

Table 1 Overview of the VR program

Components	Movements	Rational
Oculomotor exercises	VORx1	Improve gaze stability and
	VORx2	vestibulo-ocular (VOR) gain
	Smooth pursuits	adaptation
	Saccades	
Head movement exercises	Shaking the head right and left, nodding the head up and down, and circumducting the head clockwise and counterclockwise;	Habituate vestibular responses and to relieve symptoms
	while maintaining focus on a visual target	
Gait and balance training	Static standing on varied base of support (feet apart, feet together, semi-tandem, Tandem)	Facilitate the vestibulospinal response, improve postural stability, and help regain
	Static standing with different arm positions (arms away from body, arms close to body, arms reaching forward, arms tossing a ball)	balance and physical function
	Sitting to stand up	
	Sitting upright then bending down to pick up objects	

Walking with yaw head movement

Walking with pitch head movement

Tossing a ball above the eye level while

walking

Tandem walking on a level surface

Tandem walking on a foam surface

The difficulties of the tasks in each session are different according to each participant's balance performance (as measured by computerized dynamic posturography, CDP) or tolerance to vestibular stimulus. We intend to make the tasks progressively challenging. The approaches used to increase task challenge will be: (1) performing the exercises from a generally slow speed to an increased velocity; (2) change target distance (near to far) while performing VOR x1; (3) placing target in a distracting visual pattern; (4) performing the exercises with eyes open to with eyes shut; (5) with altered surface from solid surface to foam surface; (6) carrying out dual tasks such as doing math or talking on cell phone while walking.

The VR protocol consists of one office-based session each week by a skilled physiotherapist (Wu PX) at the clinic, and the other six days of home-based exercise. Compliance will be assessed during home exercise only. An exercise diary outlining the time and duration of each time exercise is required to be filled out every week. A video and booklet have been developed illustrating the program and are used as guides when participants carry out exercise at home. Figure 2 and figure 3 present the screenshots of the training video. During the first clinical visit sessions, the physiotherapist will provide adequate supervised vestibular rehabilitation for the patients to help them understand the goals of the program and ways to manage and progress

1
2
3
4 themselves independently. Patients are also instructed not to start any new physical activity during
5
6 the study period.
7

8
9 Participants in Group B (betahistine group) will be prescribed with betahistine 12mg
10
11 (manufactured by Wei Cai China Pharmaceutical Co., Ltd.), two tablets two times daily for four
12
13 weeks. Participants are asked not to take any other types of antivertiginous medicine in the course
14
15 of the study, or in case that scenario occurs, they should inform his/her ENT specialist. The
16
17 pharmacy department of the study hospital is responsible for dispensing betahistine to each
18
19 participant. There are 30 tablets in one prescription package. Four packages will be prescribed at
20
21 the commencement of treatment. During the first two follow-up visits (2-week and 4-week post
22
23 randomization), participants are asked to bring their drug packages and the specialist will count
24
25 the tablets left, if the participant fully adheres to the protocol, then 8 tablets should be left by the
26
27 4-week follow-up.
28
29
30
31
32
33

34
35 Participants allocated in Group C (VR plus betahistine group) will receive a combination of VR
36
37 and betahistine protocol as described above.
38

39 40 **Adverse events**

41
42 Adverse events are rare while performing VR. However, patients are instructed to report any
43
44 complaints or symptoms during or after performing the exercises. The following symptoms are
45
46 considered as signs to stop or modify VR protocol: vomiting, nausea or muscle soreness, a feeling
47
48 of sharp or prolonged pain in the neck, arms or legs, a feeling of ear fullness, hearing loss or
49
50 tinnitus, double vision, fainting with experience of unconsciousness or blacking out. Adverse
51
52 events will be reported to Institute of Review board of Eye & ENT Hospital of Fudan University
53
54 within 48 hours.
55
56
57
58
59
60

1
2
3
4 The tolerability judgments for betahistine were reported as good.[34] Major possible side effects
5
6 include gastrointestinal system disturbances and headache.[35] In current study, participants are
7
8 encouraged to report spontaneously of any event after betahistine intake. The investigator will
9
10 routinely contact the participant once a week and ask if there are any unexpected symptoms
11
12 coming up. Any adverse events likely caused by betahistine during the trial will be recorded and
13
14 reported to the Adverse Drug Reaction (ADR) administration of Eye & ENT Hospital of Fudan
15
16 University within 48 hours.
17
18
19
20
21

22 **Withdrawal/ retention of participants**

23
24 Participation is voluntary in this study and the participants have the right to withdraw at any time.
25
26 However, we will use approaches as recommended by Dziura et al.[36] to improve adherence to
27
28 the intervention protocols and minimize attrition rates. These include data collection not requiring
29
30 clinical appointments, a reimbursement mechanism for extra auxiliary examination fees that
31
32 encourages study completion, and the provision of weekly phone-call contact during the trial. Any
33
34 concerns, such as unexpected symptoms, as well as logistic issues such as travelling to clinic or
35
36 parking issue will be evaluated during each telephone consultation. In rare cases, participants may
37
38 be withdrawn owing to unforeseen circumstances. Every reason for withdrawal will be recorded.
39
40
41
42
43
44

45 **Outcome measures**

46
47 Evaluating therapy success in patients suffering from vestibular disorder is often difficult due to
48
49 the complexity of this condition and the lack of specific apparatus-based parameters. Various
50
51 measurements have been utilized; however, no consensus was reached as to what aspects should
52
53 be addressed. An international group of investigators and health care providers developed a core
54
55 set, based on the International Classification of Functioning, Disability and Health (ICF)
56
57
58
59
60

1
2
3
4 framework, illustrating key aspects of functioning that should be measured when assessing
5
6 patients with vertigo, dizziness, and imbalance.[37] Of which, two main domains are included: (1)
7
8 body function and structure; (2) activity and participation. Recently published evidence-based
9
10 clinical practice guideline made recommendations for specific rehabilitation outcome assessment
11
12 by using recommended measures across the ICF domains.[26] In current study, both ICF-based
13
14 activity and participation aspect and apparatus-based measures will be included to capture the
15
16 whole picture of effectiveness of VR on managing RD after successful repositioning in BPPV
17
18 patients.
19
20
21
22
23

24 ***Primary outcomes***

25
26
27 Primary outcomes are focused on patients' daily functional aspects and balance ability, which
28
29 include:
30
31

32 1. Participant's activity and participation, quantified by Vestibular Activities and Participation
33
34 (VAP) measure. The VAP is a 34-item self-report questionnaire based on ICF framework to
35
36 evaluate the effect of dizziness and/or balance problem on the ability to perform activity and
37
38 participation tasks.[38] The difficulty of each task is rated without assistance of other persons.
39
40

41
42 Each item of the VAP is set as a five-point scale indicating the level of difficulty; 0 refers to none
43
44 difficulty and 4 represents unable to do. Total score is obtained by calculating the average item
45
46 scores after excluding the "not applicable" responses. Previous study established cross-cultural
47
48 validity of VAP.[39] We recently have completed the translation and validation work of Chinese
49
50 version of VAP.
51
52

53
54 2. Balance function, measured by computerized dynamic posturography (CDP, Equitest,
55
56 NeuroCom International, Inc.). The Sensory Organization Test (SOT) of CDP evaluates the ability
57
58
59
60

1
2
3
4 of subjects to utilize vision, vestibular and somatosensory for maintaining their balance.[40] Six
5
6 increasingly challenging conditions (from SOT 1 through SOT6) that disrupt portions of balance
7
8 sensory input or visual surrounding are carried out to fulfill balance evaluation. An Equilibrium
9
10 Score (ES) for each condition is calculated by comparing the angular difference between the
11
12 subject's calculated maximum and minimum sagittal plane body sway to a theoretical maximum
13
14 displacement (12.5°). In terms of overall performance, a Composite Score (CS) is given as an
15
16 estimate of postural stability, a CS score near 100% indicates little sway, while scores approaching
17
18 0% indicate evidenced instability or fall. Both ES in each test condition from SOT 1 to SOT 6 and
19
20 the CS will be used for analysis in this study. The values are considered as abnormal when the
21
22 score is lower than the age-specific norm data.
23
24
25
26
27
28

29 30 *Secondary outcomes*

31
32 Secondary outcomes include dizziness-related handicap, recovery of otolith dysfunction, and
33
34 duration of symptoms.
35
36

37
38 1. Dizziness-related handicap measured by DHI. DHI has been widely used as a reliable tool for
39
40 evaluating the self-perceived handicap effects imposed by vestibular system disease and has been
41
42 translated and standardized for the Chinese by Ding et al. [41] The DHI consists of 25 self-
43
44 assessment items which can be broken down into three subscales: physical, emotional, and
45
46 functional. Total scores of DHI range from 0 to 100 with increasing scores indicating greater
47
48 perception of handicap because of dizziness. It has been widely used as a reliable and valid tool
49
50 for assessing the harmful effects of dizziness on QoL of patients including BPPV.[42]
51
52
53

54
55 2. Otolith function, analyzed by Vestibular Evoked Myogenic Potentials (VEMPs). VEMPs is
56
57 now established as clinical test of otolith function. Cervical VEMP (cVEMP) is used to assess
58
59
60

1
2
3
4 inferior nerve otolith function (test mainly saccular function) and ocular VEMP (oVEMP) is
5
6 believed to exam superior nerve otolith function (test mainly utricular function). Previous
7
8 studies[43, 44] identified that, in patients with BPPV underwent successful CRP, the occurrence of
9
10 residual symptoms was correlated to the abnormalities of oVEMP, suggesting that utricular
11
12 dysfunction is responsible for RD presence. Controversially, another study found that BPPV
13
14 patients with saccular dysfunction were more than those with utricular dysfunction.[42] Therefore,
15
16 in present study, both cVEMP and oVEMP will be recorded by using Bio-Logic Navigator Pro 9.0
17
18 (Natus Medical Inc., San Carlos, USA) system. The procedure will be performed in a sound-proof
19
20 room. The methodology is reported in detail elsewhere.[45] Otolith dysfunction in our patients is
21
22 defined as the lack of unilateral responses in cVEMP or oVEMP.
23
24
25
26
27
28

29
30 3. Duration of symptoms reported by patients. During the trial period, a researcher contacts the
31
32 participants once a week to probe how many days do they experience symptoms in the previous
33
34 week. By the end of the study, the reported symptoms' day of each week will be added together
35
36 representing the whole duration of symptoms.
37
38

39 40 **Timepoint of outcome measures**

41
42 Outcome measures are applied at baseline and at three follow-ups. Baseline assessments occur on
43
44 the second day following successful CRP. Demographic and clinical data collected will include:
45
46 age, gender, education, employment, marital status, coexistent systemic diseases, date of onset,
47
48 duration of symptom from onset to treatment, involved ear side and canal, the number of CRP.
49
50 Participants are required to return to clinic at 2-week, 4-week and 8-week post allocation. They
51
52 will fill out the same questionnaires (VAP and DHI) upon each follow-up, while the CDP and
53
54 VEMPs will only be repeated when the previous exam shows abnormality. Schedule of
55
56
57
58
59
60

1
2
3
4 enrollment, interventions and outcome assessments are presented in table2.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 Inventory; VEMP, Vestibular Evoked Myogenic Potential; # indicates test only be repeated when
5
6 the previous one shows abnormality.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Statistical analysis

Sample size calculation

The study sample size was based on one of the primary outcomes--- VAP measure, which is a useful clinical tool to assess a patient's limitation in activities and participation due to vertigo, dizziness, and unsteadiness. The validation study of VAP in patients who complained about dizziness or imbalance showed the minimum detectable change (MDC) for the VAP was 0.58, with a standard error of 0.21[39]. In this study, a 0.6 difference of VAP score is considered clinically meaningful. Thus, to detect an MDC of 0.6 for the VAP with 80% power (alpha level of 0.05, two-sided test), 55 per group will be required. Although there are three groups in this study, controlling for type 1 error rate is not needed because our hypotheses are: (1) VR will be better than betahistine (Group A versus Group B) and (2) VR will be non-inferior to VR plus betahistine (Group A versus Group C); therefore, only two comparisons will be executed. Allowing a 20% loss to follow-up, a total sample of 183 (61 per group) will be required for the current study.

Data Analysis

Statistical analyses will be completed using IBM SPSS Statistics for Windows (SPSS V.22.0) and the level of significance will be set at $p < 0.05$. Firstly, descriptive analysis will be conducted to determine outliers and distributions of the data. Then, the intervention group and control group will be analyzed for baseline comparability with respect to the baseline variables. Analysis of the outcome measures will be based on the conservative intention-to-treat (ITT) approach; moreover, as a secondary analysis, a per protocol analysis will also be performed. Drop-out / attrition is anticipated. We will examine the structure and pattern of missing data and, if appropriate, multiple imputation methods will be used in both ITT and the per-protocol analyses.

1
2
3
4 The main analysis of change in the primary outcomes (VAP score and SOT composite) will use
5
6 mixed-model with repeated measures (MMRM) models, with fixed effects for group and time and
7
8 a random effect for subject. Mathematical transformation or categorization of raw scores will be
9
10 undertaken to meet distributional assumptions that required in MMRM models. Models will adjust
11
12 for age, gender and other baseline potential confounders. Secondary outcomes include both
13
14 continuous data (DHI score, duration of symptoms) and dichotomous data (otolith function,
15
16 defined as normal or abnormal). Analysis of secondary outcomes will be conducted using mixed
17
18 model with repeated measures for continuous outcomes or logistic regression for dichotomous
19
20 data, again controlling for baseline potential confounders. Statistical analysis will be carried out by
21
22 a statistician from Fudan University Medical School, who is blinded to group allocation and study
23
24 hypothesis. To achieve that blinding, all participants are anonymized and study arms are coded as
25
26 A, B, C.
27
28
29
30
31
32
33
34

35 **Trail status and recruitment**

36
37 Protocol V.2.0, 10 August, 2018. Planned date of first enrolment is September 1, 2018. The
38
39 estimated time required for recruitment is 15 months. The total duration of this study is expected
40
41 to be 23 months, including statistical analysis and study results drafting.
42
43
44

45 **Data management**

46
47 Data Safety and Monitoring Board (DSMD) has already been set up. DSMD will monitor day-to-
48
49 day running of the trial, review the accumulation data, check database integrity, and be responsible
50
51 for carry out interim analyses. DSMD consists of five persons: a chair, a statistician, a
52
53 methodologist experienced in research with BPPV, a clinical expert, and a patient representative.
54
55

56
57 All members are independent from the study sponsor and report no competing interest. The
58
59
60

1
2
3
4 DSMD meets approximately every month from the start of the trial. Trial sponsor compensate
5
6 DSMD members for their time and effort, similar to the compensation provided to other trial
7
8 support personnel.
9

10
11 For data collection, an electronic case report form (CRF) has been designed to record all the data
12
13 from the baseline and the three follow-ups during the trial. Electronic data are stored on a public
14
15 platform at www.medresman.org sponsored by China clinical trial registry center. The database
16
17 uses standard techniques to provide security. Access to database is controlled by user names and
18
19 encrypted passwords. Individual participant data (IPD) will be made public in 6 months after the
20
21 completion of the study through the IPD sharing platform.
22
23
24
25

26 27 **Patient and public involvement** 28

29
30 Patients and the public were not involved in the design of this study. However, we have consulted
31
32 with a patient representative about his views on how best to involve patients throughout the
33
34 proposed project. His views have been incorporated in our revised protocol. Patients and the
35
36 public will be informed of the study results via peer-reviewed journals or academic conference.
37
38
39

40 41 **Dissemination of the study findings** 42

43 We plan to publish the study findings in peer-reviewed academic journals. We also intend to
44
45 deliver presentation of this study at local, national and international conferences where possible.
46
47 Furthermore, we will draft a summary of the study results on website of Eye & ENT hospital that
48
49 can be accessed by all trial participants as well as relevant interest groups.
50
51

52 53 **Competing interests** 54

55
56 No competing interests exist.
57

58 59 **Funding** 60

This study was supported by Science and Technology Commission of Shanghai Municipality (grant number.184119551900) and the Department of Otorhinolaryngology at Eye & ENT Hospital of Fudan University.

Ethics approval

Institute Review Board of Eye & ENT Hospital of Fudan University (reference number.2017046).

References

1. Von BM, Radtke A, Lezius F, *et al.* Epidemiology of benign paroxysmal positional vertigo: a population based study. *J Neurol Neurosurg Psychiatry* 2007;78:710-15.
2. Kim JS, Zee DS. Clinical practice. Benign paroxysmal positional vertigo. *New Engl J Med* 2014;370:1138-47.
3. Schuknecht HF, Ruby RR. Cupulolithiasis. *Adv Otorhinolaryngol* 1973; 20:434-43.
4. Epley JM. The Canalith Repositioning Procedure: For Treatment of Benign Paroxysmal Positional Vertigo. *Otolaryngol Head Neck Surg* 1992; 107:399-404.
5. Brandt T, Stedden S. Current view of the mechanism of benign paroxysmal positioning vertigo: cupulolithiasis or canalolithiasis? *J Vestib Res* 1993; 3:373-82.
6. Inagaki T, Suzuki M, Otsuka K, *et al.* Model experiments of BPPV using isolated utricle and posterior semicircular canal. *Auris Nasus Larynx* 2006; 33:129-34.
7. Bhattacharyya N, Gubbels SP, Schwartz SR, *et al.* Clinical practice guideline: benign paroxysmal positional vertigo (Update). *Otolaryngol Head Neck Surg* 2017;156(3S):S1-47.
8. Martellucci S, Pagliuca G, de Vincentiis M, *et al.* Features of Residual Dizziness after Canalith Repositioning Procedures for Benign Paroxysmal Positional Vertigo. *Otolaryngol Head Neck Surg* 2016; 49:74-78.

- 1
2
3
4 9. Swain SK BI, MC S. Role of Ginkgo biloba for controlling residual dizziness after successful
5
6 treatment of benign paroxysmal positional vertigo: Our experiences at a tertiary care teaching
7
8 hospital of Eastern India. *Int J health Allied Sci* 2018; 7:196-200.
- 9
10
11 10. Seok JI, MD, Lee HM, *et al.* Residual dizziness after successful repositioning treatment in
12
13 patients with benign paroxysmal positional vertigo. *J Clin Neurol* 2008; 3:107-16.
- 14
15
16 11. Giommetti G, Lapenna R, Panichi R, *et al.* Dizziness after Successful Repositioning Maneuver
17
18 for Idiopathic Benign Paroxysmal Positional Vertigo. *Audiol Res* 2017;178:31-7.
- 19
20
21 12. Vaduva C, Estéban-Sánchez J, Sanz-Fernández R, *et al.* Prevalence and management of post-
22
23 BPPV residual symptoms. *Eur Arch Otorhinolaryngol* 2018; 275:1429–1437
- 24
25
26 13. Lopez-Escamez JA, Gamiz MJ, Fernandez-Perez A, *et al.* Long-term outcome and health-
27
28 related quality of life in benign paroxysmal positional vertigo. *Eur Arch Otorhinolaryngol* 2005;
29
30 262:507-11.
- 31
32
33 14. Korres S, Balatsouras DG, Ferekidis E. Prognosis of patients with benign paroxysmal
34
35 positional vertigo treated with repositioning manoeuvres. *J Laryngol Otol* 2006; 120:528-33.
- 36
37
38 15. Faralli M, Lapenna R, Giommetti G, *et al.* Residual dizziness after the first BPPV episode: role
39
40 of otolithic function and of a delayed diagnosis. *Eur Arch Otorhinolaryngol* 2016, 273(10):1-9.
- 41
42
43 16. Seo T, Shiraishi K, Kobayashi T, *et al.* Residual dizziness after successful treatment of
44
45 idiopathic benign paroxysmal positional vertigo originates from persistent utricular dysfunction.
46
47
48
49
50
51 *Acta Otolaryngol* 2017; 137:1-4.
- 52
53
54 17. Kim HA, Lee H. Autonomic dysfunction as a possible cause of residual dizziness after
55
56 successful treatment in benign paroxysmal positional vertigo. *Clin Neurophysiol* 2014; 125:608-14.
- 57
58
59 18. Staab JP, Eckhardtthenn A, Horii A, *et al.* Diagnostic criteria for persistent postural-perceptual
60

1
2
3
4 dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular
5
6 Disorders of the Bárány Society. *J Vestib Res* 2017; 27:1-18.

7
8
9 19. Rubenstein L Z, Kenny R A, Eccles M, *et al.* Preventing falls in older people: new advances
10
11 and the development of clinical practice guidelines. *J R Coll Physicians of Edinb* 2003;33:262-272.

12
13
14 20. Abou-Elew MH, Shabana MI, Selim MH, *et al.* Residual postural instability in benign
15
16 paroxysmal positional vertigo. *J Audiol Med* 2011; 9:8-15.

17
18
19 21. Teggi R, Quagliari S, Gatti O, *et al.* Residual Dizziness after Successful Repositioning
20
21 Maneuvers for Idiopathic Benign Paroxysmal Positional Vertigo. *Eur Arch Otorhinolaryngol* 2011;
22
23 268:507-11.

24
25
26 22. Vugt VAV, Horst HEVD, Payne RA, *et al.* Chronic vertigo: treat with exercise, not drugs. *BMJ*.
27
28 2017;358: j3727.

29
30
31 23. Guneri EA, Kustutan O. The effects of betahistine in addition to epley maneuver in posterior
32
33 canal benign paroxysmal positional vertigo. *Otolaryngol Head Neck Surg* 2012;146(1):104-08.

34
35
36 24. Acar B, Karasen RM, Buran Y. Efficacy of medical therapy in the prevention of residual
37
38 dizziness after successful repositioning maneuvers for Benign Paroxysmal Positional Vertigo
39
40 (BPPV). *B-ENT* 2015; 11:117-21.

41
42
43 25. Hillier SL, McDonnell M. Vestibular rehabilitation for unilateral peripheral vestibular
44
45 dysfunction. *Cochrane Db Syst Rev* 2011; 2: CD005397

46
47
48 26. Hall CD, Herdman SJ, Whitney SL, *et al.* Vestibular Rehabilitation for Peripheral Vestibular
49
50 Hypofunction: An Evidence-Based Clinical Practice Guideline: from the American physical therapy
51
52 association neurology section. *J Neurol Phys Ther* 2016; 40:124-55.

53
54
55 27. Shepard NT, Telian SA, Smithwheelock M. Habituation and balance retraining therapy: A
56
57
58
59
60

1
2
3
4 retrospective review. *Neurol Clin* 1990; 8:459-75.
5

6
7 28. Herdman SJ, Blatt PJ, Schubert MC. Vestibular rehabilitation of patients with vestibular
8
9 hypofunction or with benign paroxysmal positional vertigo. *Curr Opin Neurol* 2000; 13:39-43.
10

11
12 29. Bhattacharyya N, Gubbels SP, Schwartz SR, *et al.* Clinical practice guideline: benign
13
14 paroxysmal positional vertigo. *Otolaryngol Head Neck Surg* 2017;156: S1-47.
15

16
17 30. Hillier SL, McDonnell M. Vestibular rehabilitation for unilateral peripheral vestibular
18
19 dysfunction. *Clin Otolaryngol* 2011; 36:248-49.
20

21
22 31. Bressi F, Vella P, Casale M, *et al.* Vestibular rehabilitation in benign paroxysmal positional
23
24 vertigo: Reality or fiction? *Int J Immunopathol Pharmacol* 2017; 30:113-22.
25

26
27 32. Chang WC, Yang YR, Hsu LC, *et al.* Balance improvement in patients with benign paroxysmal
28
29 positional vertigo. *Clin Rehabil* 2008; 22:338-47.
30

31
32 33. Ribeiro KM, Freitas RV, Ferreira LM, *et al.* Effects of balance Vestibular Rehabilitation
33
34 Therapy in elderly with Benign Paroxysmal Positional Vertigo: a randomized controlled trial.
35
36 *Disabil Rehabil* 2017; 39:1198-206.
37

38
39 34. Otto V, Fischer B, Schwarz M, *et al.* Treatment of vertebrobasilar insufficiency--associated
40
41 vertigo with a fixed combination of cinnarizine and dimenhydrinate. *Int Tinnitus J* 2008; 14:57-67.
42
43

44
45 35. Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. *Cochrane Db Syst*
46
47 *Rev.* 2016;6: D10696.
48

49
50 36. Dziura JD, Post LA, Zhao Q, *et al.* Strategies for Dealing with Missing Data in Clinical Trials:
51
52 From Design to Analysis. *Yale J Biol Med.* 2013; 86:343-58.
53

54
55 37. Grill E, Bronstein A, Furman J, *et al.* International Classification of Functioning, Disability
56
57 and Health (ICF) Core Set for patients with vertigo, dizziness and balance disorders. *J Vestibul*
58
59

1
2
3
4 *Res-Equil.* 2012; 22:261-71.
5

6 38. Alghwiri AA, Whitney SL, Baker CE, *et al.* The development and validation of the vestibular
7 activities and participation measure. *Arch Phys Med Rehabil* 2012; 93:1822-31.
8

9
10 39. Mueller M, Whitney SL, Alghwiri A, *et al.* Subscales of the Vestibular Activities and
11 Participation questionnaire could be applied across cultures. *J Clin Epidemiol* 2015;68: 211-19.
12

13
14 40. Nashner, LM. *Computerized dynamic posturography*. In: Jacobson GP SNE, editor *Balance*
15 *Function Assessment and Management*. San Diego: Plural Publishing; 2016.
16

17
18 41. Ding L, Liu C, Wang JX. An Evaluaiton of the Dizziness Handicap Inventory (Chinese
19 version). *Chinese Journal of Otology*. 2013;11:228-30. In Chinese
20

21
22 42. Hoseinabadi R, Pourbakht A, Yazdani N, *et al.* The effects of abnormality of cVEMP and
23 oVEMP on rehabilitation outcomes in patients with idiopathic benign paroxysmal positional vertigo.
24
25 *Eur Arch Otorhinolaryngol*. 2016; 273:643-48.
26

27
28 43. Tian Yongsheng, Zhang Yan, Ma Rong, *et al.* Features of vestibular evoked myogenic potential
29 in patients with residual dizziness after canalith repositioning procedures for benign paroxysmal
30 positional vertigo. *J Clin Otorhinolaryngol Head Neck Surg (China)* 2018; 32:845-49. In Chinese
31

32
33 44. Seo T, Shiraishi K, Kobayashi T, *et al.* Residual dizziness after successful treatment of
34 idiopathic benign paroxysmal positional vertigo originates from persistent utricular dysfunction.
35
36 *Acta Otolaryngol*. 2017; 137:1-4.
37

38
39 45. Zhou YJ, Wu YZ, Cong N, *et al.* Contrasting results of tests of peripheral vestibular function
40 in patients with bilateral large vestibular aqueduct syndrome. *Clin Neurophysiol*. 2017; 128:1513-
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 Study flow chart.

Figure 2 Screenshot of head movement exercises in the training video.

Figure 3 Screenshot of gait exercise in the training video.

For peer review only




Figure 1 Study flow chart

254x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 2 Screenshot of head movement exercises in the training video

285x160mm (300 x 300 DPI)



Figure 3 Screenshot of gait exercises in the training video

528x297mm (96 x 96 DPI)

BMJ Open

The effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning manoeuvres in patients with benign paroxysmal positional vertigo : a protocol for a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026711.R2
Article Type:	Protocol
Date Submitted by the Author:	02-Mar-2019
Complete List of Authors:	wu, Peixia; Eye & ENT Hospital of Fudan University Cao, Wenzhu; Eye and ENT Hospital of Fudan University, intensive care unit Hu, Yan; School of Nursing, Fudan University Li, Huawei; Eye & ENT Hospital of Fudan University, Department of Otorhinolaryngology
Primary Subject Heading:	Ear, nose and throat/otolaryngology
Secondary Subject Heading:	Ear, nose and throat/otolaryngology
Keywords:	benign paroxysmal positional vertigo, vestibular rehabilitation, dizziness, randomized controlled trial

SCHOLARONE™
Manuscripts

1
2
3
4 **The effects of vestibular rehabilitation, with or without betahistine, on managing residual**
5
6 **dizziness after successful repositioning manoeuvres in patients with benign paroxysmal**
7
8 **positional vertigo : a protocol for a randomized controlled trial**
9
10

11 Wu Peixia,¹ Cao Wenzhu,² Hu Yan,³ Li Huawei⁴

12
13
14 1. Department of operation room, Eye and ENT Hospital of Fudan University, Shanghai, China

15
16
17 2. Intensive care unit, Eye and ENT Hospital of Fudan University, Shanghai, China

18
19
20 3. School of Nursing, Fudan University, Shanghai, China

21
22 4. Department of Otorhinolaryngology, Eye and ENT Hospital of Fudan University, Shanghai,
23
24
25 China

26
27 Co-Corresponding author: Dr. Li Huawei, Head of Department of Otorhinolaryngology, Eye and
28
29
30 ENT Hospital of Fudan University, No.83 Fenyang Road, Shanghai, 200031, China; Tel: 86-21-
31
32 64377134-669; E-mail: hwli@shmu.edu.cn

33
34
35 Co-Corresponding author: Dr. Yan Hu, President of School of Nursing, Fudan University, No.305
36
37
38 Fenling Road, Shanghai, 200031, China; E-mail: fudanhuyan@163.com

ABSTRACT

Introduction

Benign paroxysmal positional vertigo (BPPV) is recognised as the leading cause of peripheral vertigo in adults. The canalith repositioning procedure (CRP) can be used for effective treatment of BPPV. However, some patients experience residual dizziness (RD) even after successful CRP, resulting in a significant negative impact on their daily function and quality of life. Exercise-based vestibular rehabilitation (VR) has been proven as an effective method for managing dizziness and has been applied in patients with various vestibular disorders. However, the efficacy of VR to specifically target RD post-BPPV is unknown. This study aims to investigate the efficacy of VR, compared to betahistine or VR plus betahistine treatment, in the treatment of patients experiencing RD after successful CRP.

Methods and analysis

A randomised single-blinded controlled trial will be carried out to determine the efficacy of VR compared to betahistine or VR plus betahistine treatment in mitigating RD and improving balance function. Patients with BPPV who experience RD after successful CRP will be recruited. Participants will be randomised into one of three groups to receive VR, betahistine, or VR plus betahistine. There will be 61 participants in each group. The primary outcomes will be changes in the patient's daily function as measured by the Vestibular Activities and Participation questionnaire and balance ability assessed by computerised dynamic posturography. The secondary outcomes will be dizziness-related handicap, otolith function, and duration of RD symptoms.

Outcome measures will be noted at baseline and at 2, 4, and 8 weeks post-randomisation. This study has the potential to reduce unnecessary anti-vertigo drug prescriptions and may lead to a

1
2
3
4 general consensus regarding the use of VR as a first-line treatment for RD in patients with BPPV.
5

6
7 **Ethics and dissemination**
8

9 This trial received ethical approval from the Institutional Review Board of Eye & ENT Hospital of
10
11 Fudan University (reference number.2017046). The study results will be disseminated via peer-
12
13 reviewed journals and conferences.
14
15

16
17 ClinicalTrials.gov identifier: NCT03624283
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and limitations of this study

► To the best of our knowledge, this is the first randomised controlled trial to evaluate the effects of vestibular rehabilitation (VR), compared to betahistine or VR in addition to betahistine, on managing residual dizziness after successful canalith repositioning procedure in patients with benign paroxysmal positional vertigo.

► Both subjective and objective outcome measures will be comprehensively assessed with a reasonably long follow-up period. In particular, patients' activities and participation aspect based on the International Classification of Functioning, Disability and Health framework will be evaluated. Such a trial will be able to fully reflect the efficacy of the proposed intervention.

► For practical reasons, there will be no control group with sham, placebo, or no treatment in this study; therefore, the study will not be useful to determine whether participants improve spontaneously or to determine the mechanisms by which the three interventions may function to alter outcomes.

INTRODUCTION

Benign paroxysmal positional vertigo (BPPV) is the leading cause of peripheral vertigo, with a prevalence of 10.7-64 per 100,000 people and a lifetime prevalence of 2.4%. [1] The time at onset is most commonly between the fifth and seventh decade of life, but BPPV can occur at any age. [2] Two hypotheses, involving cupulolithiasis [3] and canalithiasis, [4] are among the most widely accepted hypotheses that elucidate the pathophysiology of BPPV. The hypothesis involving canalithiasis has gained wider acceptance in the scientific field because it offers a better explanation of the symptoms. [5] According to the canalithiasis hypothesis, BPPV is caused by free otoconia dislodging from the utricular macula and entering the semicircular canal, which promotes inappropriate flow of endolymph whenever the head is rotated in the plane of the affected canal. [4] Although any of the three semicircular canals can be affected, the posterior semicircular canal is the most common, followed by the horizontal canal. Treatment for BPPV consists of the canalith repositioning procedure (CRP) with the aim of repositioning the displaced particles from the affected canal to their original location. [6] The CRP has long been a mainstay therapy and is now well established as the gold treatment for BPPV. [7] Posterior canal BPPV can be treated by performing Epley's manoeuvre or Semont's liberatory manoeuvre. For horizontal canal BPPV, barbecue rotation or the Gufoni manoeuvre have been demonstrated to be effective.

Despite the fact that the CRP can provide rapid relief of vertigo in patients with BPPV, residual symptoms may remain even after the disappearance of typical vertigo and nystagmus following a successful CRP. These residual symptoms, also referred to as residual dizziness (RD), imply a non-specific sensation of unsteadiness, lightheadedness, disorientation, fogginess, or drowsiness. [8] The reported incidence of RD ranges from 29.6% to 76.9%, and the duration of RD

1
2
3
4 can range from a few days to several months.[8-12] Several authors have reported that RD
5
6 symptoms may persist for >3 months,[13,14] resulting in adverse physical and psychological
7
8 consequences.
9

10
11 Different pathophysiological mechanisms have been proposed to explain the presence of RD,
12
13 but the cause remains unknown. Previous studies have suggested the following possible
14
15 explanations: (1) the persistence of debris in the canal is insufficient to provoke detectable
16
17 positional nystagmus or vertigo;[11] (2) otolith dysfunction;[15,16] (3) coexisting vestibular
18
19 disease that leads to incomplete central adaptation; (4) potential autonomic dysfunction such as
20
21 orthostatic hypotension;[17] and (5) persistent postural-perceptual dizziness.[18]
22
23
24
25

26
27 Dizziness increases the risk of falls or fear of falling, disturbs daily life, and results in
28
29 restriction of social activities. As a result, many patients with BPPV tend to avoid certain
30
31 activities, limit their movement, and avoid specific circumstances due to fear of provoking
32
33 dizziness and unanticipated unsteadiness attacks.[19] It is not surprising that increased postural
34
35 instability has been documented in patients who experience RD.[20, 21] Given the high
36
37 prevalence of RD after successful repositioning and its negative impact on patient recovery, this
38
39 impairment should be managed properly.
40
41
42
43
44

45
46 To date, there is no consensus regarding how to effectively manage RD after successful CRP
47
48 in patients with BPPV. Betahistine is the most widely used medication to ameliorate dizziness due
49
50 to its effects of increasing labyrinthine microcirculation as well as suppressing the increased
51
52 neuronal activity in vestibular receptor cells, afferent neurons, and vestibular nuclei.[11,22]
53
54 However, conflicting data exist regarding the efficacy of betahistine for preventing or treating RD.
55
56
57
58 Guneri et al.[23] evaluated the efficacy of betahistine in reducing symptoms after Epley's
59
60

1
2
3
4 manoeuvre for posterior canal BPPV; they found that 48 mg of daily betahistine was more
5
6 effective than Epley's manoeuvre alone or combined with a placebo in improving symptoms as
7
8 assessed by four different vertigo symptoms scales. In contrast, Acar et al.[24] carried out a
9
10 randomised controlled clinical trial to investigate the efficacy of betahistine (compared to a no
11
12 medication group) for the treatment of RD after successful CRP. After 3 and 5 days of treatment,
13
14 the mean Dizziness Handicap Inventory (DHI) scores of the groups receiving medication did not
15
16 differ from the mean DHI score of the control group, indicating that betahistine did not produce
17
18 greater alleviation of RD than did no treatment. However, both studies have unclear randomisation
19
20 sequence generation and allocation concealment and only included subjective outcomes. These
21
22 results suggest that clinical trials with more rigorous methodology and that include comprehensive
23
24 outcome assessments are warranted.
25
26
27
28
29
30
31

32 Recently, non-pharmacological interventions such as vestibular rehabilitation (VR) have been
33
34 recommended as the first line treatment for chronic vertigo.[22] VR, which has been available
35
36 since the 1940s, is an exercise-based treatment consisting of varied eye, head, and body
37
38 movements designed to stimulate the vestibular system and optimise vestibular compensation.[25]
39
40 The current VR approach typically includes a combination of three different exercise components
41
42 to address the impairments or functional limitations identified during evaluation: (1) gaze stability
43
44 exercises; (2) habituation exercises, including optokinetic exercises; and (3) balance and gait
45
46 training in different conditions.[26] The aim of VR is to improve the visual-vestibular interaction
47
48 and increase balance ability. It is also proven to improve daily function and reduce the symptoms
49
50 of dizziness.[26] The mechanism underlying its efficacy is thought to rely on the following three
51
52 aspects: (1) compensation/habituation, a central process referring to the concept that repeated
53
54
55
56
57
58
59
60

1
2
3
4 exposure to a provocative stimulus will result in a reduction in the symptomatic response to that
5
6 treatment;[27] (2) adaptation, which is the recovery of dynamic vestibulo-ocular responses due to
7
8 the ability of the vestibular system to make long-term changes in the neuronal response to input;
9
10 and (3) substitution, which is the use of other strategies to replace the lost function.[28]
11
12
13

14 The updated evidence-based clinical guideline of the American Academy of Otolaryngology-
15
16 Head and Neck Surgery Foundation (AAO-HNSF) indicates that the clinician should offer VR as
17
18 treatment for BPPV, stating that although movement/ habituation-based VR should not be a first-
19
20 line treatment modality for BPPV, it is indicated for patients who experience persistent disability
21
22 following CRP.[29] VR is particularly indicated in subjects with additional impairments, such as
23
24 nonspecific dizziness and heightened fall risk.[7] A Cochrane review[30] was conducted to assess
25
26 the efficacy of VR in patients with symptomatic unilateral peripheral vestibular dysfunction; this
27
28 included eight studies investigating VR in BPPV specifically. This review supports the contention
29
30 that the primary intervention for BPPV should be CRP that directly treat the condition, but
31
32 movement/habituation-based VR will further aid and benefit long-term functional recovery. A
33
34 more recent review by Bressi et al.[31] proposed that a hierarchy of interventions should be
35
36 offered to patients with BPPV, starting with CRP and followed by post-treatment exercises. The
37
38 findings also indicated that CRP and VR seem to have a synergic effect in patients with
39
40 BPPV.[31]
41
42
43
44
45
46
47
48
49

50 While previous studies have shed light on the benefits of VR in BPPV patients, to date, no
51
52 randomised clinical trial has been conducted to specifically investigate VR, with or without
53
54 betahistine, in treating RD following CRP in patients with BPPV. This study has been designed
55
56 with the broad aim of verifying the efficacy of VR as a first-line treatment option for RD. It
57
58
59
60

1
2
3
4 conforms to the current recommendations for best clinical practice with respect to the
5
6 implementation of VR for persons with impairments and functional limitations related to
7
8 vestibular deficit.[26] We hypothesise that participants in the VR group will exhibit fewer activity
9
10 and participation restrictions and less balance dysfunction than participants in the betahistine
11
12 group. Moreover, we expect that participants in the VR group will experience shorter durations of
13
14 RD, reduced dizziness-related handicaps, and enhanced recovery of otolith dysfunction. We also
15
16 hypothesise that the effects of VR alone will be non-inferior to a combination of VR and
17
18 betahistine in terms of the outcome measurements mentioned above.
19
20
21
22
23

24 **METHODS AND ANALYSIS**

25 **Study design, setting, and participants**

26
27 This study was designed as a randomised controlled prospective single-blinded study.
28
29 Outcome assessment will be conducted by two researchers who are blinded to group allocations.
30
31
32

33
34 The study setting is the largest ear, nose, and throat (ENT)-specialised hospital in China. The
35
36 hospital serves a population of ~23 million persons in Shanghai. It also serves as a referral centre
37
38 accepting patients from all over the country.
39
40
41

42
43 The eligibility criteria are as follows: (1) diagnosis of unilateral BPPV (unilateral posterior
44
45 semicircular canal BPPV or horizontal semicircular canal BPPV) according to the clinical practice
46
47 guideline by AAO-HNSF in 2017,[29] (2) age 18-80 years, and (3) residual symptoms after
48
49 successful repositioning manoeuvres. Participants will be excluded if they (1) are confirmed to
50
51 have anterior semicircular canal BPPV or multi-canal BPPV; (2) are confirmed to have recurrent
52
53 BPPV; (3) are diagnosed with coexisting vestibular disorders, including Meniere disease,
54
55 vestibular neuritis, labyrinthitis, and peripheral vestibular loss; (4) are diagnosed with severe
56
57
58
59
60

1
2
3
4 cervical spine disease; (5) are diagnosed with severe cardiovascular disease; (6) are diagnosed
5
6 with known cerebral vascular disease such as carotid stenosis; (7) are pregnant/ lactating or
7
8 planning to become pregnant during the study period; or (8) have taken vestibulosuppressants,
9
10 antihistamines, and/or ototoxic medications in the previous 3 months.
11
12

13 14 **Procedure**

15
16
17 The study protocol was reviewed and approved by the Institutional Review Board of the Eye
18
19 & ENT Hospital of Fudan University (Reference Number: 2017046). Patients who are suspected
20
21 of having BPPV and visit an ENT specialist are potentially eligible for this study. They will
22
23 undergo a Dix-Hallpike test, a roll test, and an anterior canal provoking test to confirm whether
24
25 they are experiencing solely unilateral posterior canal or horizontal canal BPPV. After diagnosis
26
27 by an ENT specialist, posterior canal BPPV will be treated using Epley's manoeuvre or Semont's
28
29 liberatory manoeuvre, while horizontal canal BPPV will be treated with barbecue rotation
30
31 manoeuvres. The same physiotherapist will apply both the testing procedure and the CRP
32
33 manoeuvre. The CRP is repeated up to three times over the course of 1 day. After a successful
34
35 repositioning manoeuvre, patients will be asked to complete a DHI test. Patients who fail to
36
37 respond when up to three CRPs have been performed will not be included in this study.
38
39
40
41
42
43
44

45
46 On the second day following successful CRP, a lead investigator will contact the patient by
47
48 either telephone or Webchat. Patients will be asked whether they are experiencing residual
49
50 symptoms. If yes, they will be initially screened via telephone interview, and those who meet the
51
52 inclusion criteria will be invited to participate in the study. A face-to-face interview will be
53
54 arranged for patients who express an interest in the trial, written informed consent will be obtained
55
56 from candidates who agree to participate. After obtaining written consent, the principal
57
58
59
60

1
2
3
4 investigator (Li HW) will fully review the participant's medical history and perform a physical
5
6 examination and videonystagmography (VNG) including a caloric test to exclude any central
7
8 nervous system pathologies or other vestibular diseases. The diagnostic test for BPPV will be
9
10 repeated to confirm that the exclusionary characters are negative. Pure-tone audiometry and
11
12 tympanometry will be checked. Gait and balance will also be assessed (Romberg, sharpened
13
14 Romberg). Whenever necessary, an imaging exam such as a computed tomography scan or
15
16 magnetic resonance imaging will be used to exclude cerebellar disorders. The purpose of the
17
18 above-mentioned examination is to confirm the diagnosis and validate the homogeneity of all
19
20 participants who take part in the study. After eligibility screenings, participants will be randomly
21
22 allocated to one of three groups: Group A patients will perform VR exercises; Group B patients
23
24 will be prescribed betahistine; and Group C patients will be offered both VR and betahistine.
25
26 Outcome measurements will be noted at baseline and at 2, 4, and 8 weeks post-randomisation.
27
28 Outcome measurements will be executed by two independent researchers; one will be responsible
29
30 for apparatus-based measures and another for subjective data collecting. Both researchers will be
31
32 unaware of the treatment assignment until the end of the study. A study flow chart is provided in
33
34 Figure 1.

35 **Randomisation and blinding**

36
37
38 Participants will be randomly assigned to three groups of 61 persons each. The randomisation
39
40 process will be carried out by an internet-based randomisation tool provided by the China clinical
41
42 trial registration centre. The website is accessible to the public via
43
44 <http://www.medresman.org/login.aspx>. The randomisation sequence will be generated
45
46 automatically when the administrator logs into the website and requests the allocation number
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(once an eligible patient is recruited). Participants will be randomly allocated at a ratio of 1:1:1 and stratified by sex and age (≤ 60 years, >60 years). As the randomisation is on-line and automatic, neither the researchers nor the patients can manipulate which treatment the patients will receive; this ensures that group allocations are randomly assigned.

Since VR is an operational intervention, it is not possible for either the patients or the physiotherapists and physicians to be blinded to allocation. However, two independent researchers will contact the patients to collect both subjective and apparatus-based data. The statistician of our trial team will remain blinded until the statistical analyses are complete.

Interventions

Participants in Group A (VR group) will perform VR exercises twice a day, 7 days per week, over a period of 4 weeks. The exercise protocol was developed based on clinical experience and adapted from previous studies[32,33] in which vestibular stimulation exercise was demonstrated to improve balance ability and functional performance among BPPV patients who had undergone CRP. A dedicated physiotherapist (Wu PX) drafted the initial protocol. The content was reviewed by three experts with experience in caring for patients with chronic dizziness and was then piloted with two female and two male patients who have experienced RD post-BPPV. Participants reported no difficulties in practicing these exercises. The protocol primarily consists of three categories: oculomotor exercises, head movement exercises, and gait and balance training (Table 1).

Table 1. Overview of the VR program

Components	Movements	Rationale
Oculomotor	VOR \times 1	Improve gaze stability and

1			
2			
3			
4	exercises	VOR × 2	VOR gain adaptation
5			
6		Smooth pursuits	
7			
8			
9		Saccades	
10			
11	Head	Shaking the head right and left, nodding the	Habituate vestibular responses
12			
13			
14	movement	head up and down, and circumducting the	and relieve symptoms
15			
16			
17	exercises	head clockwise and counter clockwise	
18			
19		while maintaining focus on a visual target	
20			
21			
22	Gait and	Static standing on varied base of support	Facilitate the vestibulospinal
23			
24	balance	(feet apart, feet together, semi-tandem,	response, improve postural
25			
26			
27	training	tandem)	stability, and regain balance
28			
29			
30		Static standing with different arm positions	and physical function
31			
32		(arms away from body, arms close to body,	
33			
34			
35		arms reaching forward, arms tossing a ball)	
36			
37		Sitting to upright	
38			
39			
40		Sitting upright then bending down to pick	
41			
42			
43		up objects	
44			
45		Walking with yaw head movement	
46			
47			
48		Walking with pitch head movement	
49			
50			
51		Tossing a ball above the eye level while	
52			
53		walking	
54			
55			
56		Tandem walking on a level surface	
57			
58			
59		Tandem walking on a foam surface	
60			

1
2
3
4 VOR, vestibulo-ocular reflex.
5

6 The difficulties of the tasks in each session are set according to each participant's balance
7 performance (as measured by computerised dynamic posturography [CDP]) or tolerance to
8 vestibular stimulation. We intend to make the tasks progressively challenging. The approaches
9 used to increase the level of difficulty will be as follows: (1) increasing the velocity of exercise
10 performance; (2) changing target distance (near to far) while performing $VOR \times 1$; (3) placing the
11 target in a distracting visual pattern; (4) performing the exercises with eyes open, then with eyes
12 closed; (5) altering the surface from solid to foam; and (6) performing dual tasks such as doing
13 math or talking on a cell phone while walking.
14
15
16
17
18
19
20
21
22
23
24
25

26 The VR protocol involves one office-based session per week conducted by a skilled
27 physiotherapist (Wu PX) at the clinic and home-based exercises for the remaining 6 days of the
28 week. Compliance will be assessed during home exercise; an exercise diary outlining the time and
29 duration of each exercise is required to be filled out every week. A video and booklet have been
30 developed illustrating the program and will be used as guides when participants carry out exercise
31 at home. Figures 2 and 3 present the screenshots of the training video; written consent from the
32 person in the video has been obtained. During the first clinical visit, the physiotherapist will
33 provide adequate supervised VR for the patients to help them understand the goals of the program
34 and methods to manage their own progress independently. Patients will be instructed not to start
35 any new physical activity during the study period.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Participants in Group B (betahistine group) will be prescribed betahistine 12 mg
53 (manufactured by Wei Cai China Pharmaceutical Co., Ltd.) (two tablets taken twice daily for 4
54 weeks). Participants will be asked not to take any other types of antivertiginous medicine during
55
56
57
58
59
60

1
2
3
4 the course of the study; in such a case, the patient should inform his/her ENT specialist. The
5
6 pharmacy department of the study hospital will be responsible for dispensing betahistine to each
7
8 participant. There are 30 tablets in one prescription package. Four packages will be prescribed at
9
10 the commencement of treatment. During the first two follow-up visits (2 and 4 weeks post-
11
12 randomisation), participants will be asked to bring their drug packages and the specialist will
13
14 count the remaining tablets; if the participant fully adheres to the protocol, eight tablets should be
15
16 left at the 4th week follow-up visit.
17
18
19
20
21

22 Participants allocated to Group C (VR plus betahistine group) will receive a combination of
23
24 the VR and betahistine protocols as described above.
25
26

27 **Adverse events**

28
29 Adverse events are rare while performing VR. However, patients will be instructed to report
30
31 any complaints or symptoms occurring during or after the exercises. The following symptoms are
32
33 considered as signs to stop or modify the VR protocol: vomiting, nausea, or muscle soreness; a
34
35 sharp or prolonged pain sensation in the neck, arms, or legs; a sensation of ear fullness, hearing
36
37 loss, or tinnitus; double vision; or fainting.
38
39
40
41
42

43 The tolerability for betahistine is reported to be good.[34] Major possible side effects include
44
45 gastrointestinal system disturbances and headache.[35] In this study, participants will be
46
47 encouraged to report any adverse events after betahistine intake. The investigator will routinely
48
49 contact the participant once per week and ask if any unexpected symptoms have appeared. Any
50
51 adverse events likely caused by betahistine during the trial will be recorded and reported to the
52
53 Adverse Drug Reaction administration of the Eye & ENT Hospital of Fudan University within 48
54
55 h.
56
57
58
59
60

Withdrawal/retention of participants

Participation in this study is voluntary and participants have the right to withdraw at any time. However, we will use the approaches recommended by Dziura et al.[36] to improve adherence to the intervention protocols and minimise attrition rates. These include data collection that does not require clinical appointments, a reimbursement mechanism for extra auxiliary examination fees to encourage study completion, and the provision of weekly phone-call contact during the trial. Any concerns, such as unexpected symptoms, as well as logistic issues such as travelling to the clinic or parking issues will be evaluated during each telephone consultation. In rare cases, participants may withdraw owing to unforeseen circumstances. Every reason for withdrawal will be recorded.

Outcome measures

Evaluating therapeutic success in patients experiencing vestibular disorder is often difficult due to the complexity of this condition and the lack of specific apparatus-based parameters. Various measurements have been utilised; however, no consensus has been reached as to which aspects should be addressed. An international group of investigators and health care providers developed a core set based on the International Classification of Functioning, Disability and Health (ICF) framework that illustrates key aspects of functioning that should be measured when assessing patients with vertigo, dizziness, and imbalance.[37] Of these, two main domains are included: (1) body function and structure and (2) activity and participation. A recently published evidence-based clinical practice guideline has made recommendations for specific rehabilitation outcome assessment by using recommended measures from across the ICF domains.[26] In the current study, ICF-based activity and participation aspect and apparatus-based measures will be

1
2
3
4 included to provide a full overview of the efficacy of VR on managing RD after successful
5
6 repositioning in BPPV patients.
7

8 9 **Primary outcomes**

10
11 The primary outcomes will focus on patients' daily functional aspects and balance ability,
12
13 which include:
14

15
16
17 1. The participant's activity and participation as quantified by the Vestibular Activities and
18
19 Participation (VAP) scale. The VAP is a 34-item self-reporting questionnaire based on the ICF
20
21 framework to evaluate the effect of dizziness and/or balance problems on the ability to perform
22
23 activity and participation tasks.[38] The difficulty of each task (without assistance from other
24
25 persons) is rated. Each item of the VAP is scored on a five-point scale indicating the level of
26
27 difficulty; 0 refers to no difficulty and 4 indicates inability to complete the task. A total score is
28
29 obtained by calculating the average item scores after excluding the "not applicable" responses.
30
31 Previous studies have established the cross-cultural validity of the VAP.[39] We recently
32
33 completed the translation and validation of a Chinese version of the VAP.
34
35
36
37
38

39
40 2. Balance function, as measured by CDP (Equitest, NeuroCom International, Inc.). The
41
42 Sensory Organization Test (SOT) of CDP evaluates the ability of subjects to utilise vision
43
44 (vestibular and somatosensory) to maintain their balance.[40] Six increasingly challenging
45
46 conditions (from SOT1 to SOT6) that disrupt portions of balance sensory input or visual
47
48 surroundings are provided to evaluate balance. An Equilibrium Score (ES) for each condition is
49
50 calculated by comparing the angular difference between the subject's calculated maximum and
51
52 minimum sagittal plane body sway to a theoretical maximum displacement (12.5°). In terms of
53
54 overall performance, a Composite Score (CS) is given as an estimate of postural stability: a CS
55
56
57
58
59
60

1
2
3
4 score near 100% indicates little sway, while scores approaching 0% confirm instability or a fall.

5
6 The ES for each test condition from SOT1 to SOT6 and the CS will be used for analysis in this
7
8
9 study. The values are considered abnormal when the score is lower than the age-specific norm
10
11
12 data.

13 14 **Secondary outcomes**

15
16
17 The secondary outcomes will include dizziness-related handicap, recovery of otolith
18
19 dysfunction, and duration of symptoms.

20
21
22 1. Dizziness-related handicap as measured by the DHI. The DHI has been widely used as a
23
24 reliable tool for evaluating the self-perceived handicap effects imposed by vestibular system
25
26 disease and has been translated to Chinese and standardised by Ding et al.[41] The DHI consists
27
28 of 25 self-assessment items that can be broken down into three subscales: physical, emotional, and
29
30 functional. Total scores of the DHI range from 0 to 100 with increasing scores indicating greater
31
32 perception of handicap due to dizziness. It has been widely used as a reliable and valid tool for
33
34 assessing the harmful effects of dizziness on quality of life for patients including those with
35
36 BPPV.[42]

37
38
39
40
41
42 2. Recovery of otolith function as analysed by Vestibular Evoked Myogenic Potentials
43
44 (VEMPs). VEMPs are now established as a clinical test of otolith function. The cervical VEMP
45
46 (cVEMP) is used to assess inferior nerve otolith function (testing mainly saccular function), while
47
48 the ocular VEMP (oVEMP) is believed to examine superior nerve otolith function (testing mainly
49
50 utricular function). Previous studies[43,44] identified that, in patients with BPPV who underwent
51
52 successful CRP, the occurrence of residual symptoms was correlated with oVEMP abnormalities;
53
54 this suggests that utricular dysfunction is responsible for RD presence. In contrast, another study
55
56
57
58
59
60

1
2
3
4 found that BPPV patients with saccular dysfunction experienced more significant effects than did
5
6 those with utricular dysfunction.[42] Therefore, in this study, both cVEMP and oVEMP will be
7
8 recorded using the Bio-Logic Navigator Pro 9.0 (Natus Medical Inc., San Carlos, USA) system.
9
10
11 The procedure will be performed in a sound-proof room. The methodology is reported in detail
12
13 elsewhere.[45] Otolith dysfunction in our patients will be defined as a lack of unilateral responses
14
15 in cVEMPs or oVEMPs.
16
17

18
19 3. Duration of symptoms as reported by patients. During the trial period, a researcher will
20
21 contact the participants once per week to ask how many days they experienced symptoms in the
22
23 previous week. By the end of the study, the number of days per week with reported symptoms will
24
25 be summed to represent the duration of symptoms.
26
27
28

29 30 **Time-points of outcome measurements**

31
32 Outcome measurements will be performed at baseline and at three follow-up visits. Baseline
33
34 assessments will be performed on the second day following successful CRP. Demographic and
35
36 clinical data collected will include: age, sex, education, employment, marital status, coexisting
37
38 systemic diseases, date of onset, duration of symptoms from onset to treatment, affected ear and
39
40 canal, and the number of CRPs performed. Participants are required to return to the clinic at 2, 4,
41
42 and 8 weeks post-allocation. They will fill out the same questionnaires (VAP and DHI) at each
43
44 follow-up, while the CDP and VEMPs will only be repeated when the previous exam indicates
45
46 abnormality. The schedule of enrolment, interventions, and outcome assessments are presented in
47
48
49
50
51
52
53 Table 2.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

oVEMP, ocular Vestibular Evoked Myogenic Potential; cVEMP, cervical Vestibular Evoked Myogenic Potential. # Test is only repeated when the previous exam indicates abnormality.

For peer review only

Sample size calculation

The study sample size was based on the VAP measure (one of the primary outcomes), which is a useful clinical tool for assessing a patient's limitations in activities and participation due to vertigo, dizziness, and unsteadiness. The validation of VAP in patients who complained of dizziness or imbalance showed the minimum detectable change (MDC) for the VAP was 0.58, with a standard error of 0.21.[39] In this study, a VAP difference of 0.6 will be considered clinically meaningful. Thus, to detect an MDC of 0.6 for the VAP with 80% power (alpha level of 0.05, two-tailed test), 55 subjects per group will be required. Although there are three groups in this study, controlling for the type I error rate is not needed because our hypotheses are: (1) VR will be superior to betahistine (Group A versus Group B) and (2) VR will be non-inferior to VR plus betahistine (Group A versus Group C); therefore, only two comparisons will be executed. Allowing for a 20% loss during the follow-up period, a total sample of 183 (61 per group) will be required for the current study.

Data analysis

Statistical analyses will be completed using IBM SPSS Statistics for Windows (SPSS V.22.0) and the level of significance will be set at $p < 0.05$. First, a descriptive analysis will be conducted to determine outliers and the distributions of the data. The three groups will then be analysed with respect to baseline values. Analysis of the outcome measures will be based on the conservative intention-to-treat (ITT) approach; moreover, as a secondary analysis, a per protocol analysis will also be performed. Drop-out/attrition is anticipated. We will examine the structure and pattern of missing data and, if appropriate, multiple imputation methods will be used in both the ITT and the per-protocol analyses.

1
2
3
4 The main analysis of change in the primary outcomes (VAP score and SOT composite) will
5
6 use mixed-model with repeated measures (MMRM) analyses of variance (ANOVAs), with group
7
8 and time as fixed effects and subject as a random effect. Mathematical transformation or
9
10 categorisation of raw scores will be undertaken to meet the distributional assumptions that are
11
12 required in MMRM models. Models will adjust for age, sex and other baseline potential
13
14 confounders. Secondary outcomes include both continuous data (DHI score, duration of
15
16 symptoms) and dichotomous data (otolith function, defined as normal or abnormal). Analysis of
17
18 secondary outcomes will be conducted using MMRM ANOVAs for continuous outcomes or
19
20 logistic regression for dichotomous data, again controlling for baseline potential confounders.
21
22 Statistical analysis will be carried out by a statistician from Fudan University Medical School,
23
24 who will be blinded to group allocations and the study hypotheses. To achieve blinding, all
25
26 participants will be anonymised and study groups will be coded as A, B, C.
27
28
29
30
31
32
33

34 35 **Study status and recruitment**

36
37 This is protocol V.3.0, updated 20 February 2019. The planned date of first enrolment is 1
38
39 April 2019. The estimated time required for recruitment is 15 months. The total duration of this
40
41 study is expected to be 23 months, including statistical analysis and drafting of the study results.
42
43
44

45 **Data management**

46
47 The Data Safety and Monitoring Board (DSMD) has been organised. The DSMD will
48
49 monitor the day-to-day running of the trial, review the accumulation data, check the database
50
51 integrity, and be responsible for carrying out interim analyses. The DSMD consists of five
52
53 persons: a chair, a statistician, a methodologist experienced in research with BPPV, a clinical
54
55 expert, and a patient representative. All members are independent of the study sponsor and report
56
57
58
59
60

1
2
3
4 no competing interests. The DSMD will meet approximately once per month from the start of the
5
6 trial. The trial sponsor will compensate DSMD members for their time and effort, similar to the
7
8 compensation provided to other trial support personnel.
9
10

11 For data collection, an electronic case report form has been designed to record all of the data
12
13 at baseline and the three follow-up visits during the trial. Electronic data will be stored on a public
14
15 platform at www.medresman.org, which is sponsored by the China Clinical Trial Registry. The
16
17 database uses standard techniques to provide security. Access to the database is controlled by
18
19 usernames and encrypted passwords. Individual participant data (IPD) will be made public at 6
20
21 months after the completion of the study via the IPD sharing platform.
22
23
24
25
26

27 **Patient and public involvement**

28
29 Patients and the public were not involved in the design of this study. However, we have
30
31 consulted with a patient representative about his views on how best to involve patients throughout
32
33 the proposed project. His views have been incorporated into our revised protocol. Patients and the
34
35 public will be informed of the study results via peer-reviewed journals or academic conferences.
36
37
38
39

40 **ETHICS AND DISSEMINATION**

41
42 This study has received ethical approval from the Institutional Review Board of Eye & ENT
43
44 Hospital of Fudan University (reference number.2017046).
45
46
47

48 We plan to publish the study findings in peer-reviewed academic journals. We also intend to
49
50 present this study at local, national, and international conferences where possible. Furthermore, we
51
52 will draft a summary of the study results to be posted on the website of Eye & ENT hospital that
53
54 can be accessed by all trial participants as well as relevant interest groups.
55
56
57

58 **References**

- 1
2
3
4 1. Von BM, Radtke A, Lezius F, *et al.* Epidemiology of benign paroxysmal positional vertigo: a
5
6 population based study. *J Neurol Neurosurg Psychiatry* 2007;78:710-15.
7
8
- 9 2. Kim JS, Zee DS. Clinical practice. Benign paroxysmal positional vertigo. *New Engl J Med*
10
11 2014;370:1138-47.
12
13
- 14 3. Schuknecht HF, Ruby RR. Cupulolithiasis. *Adv Otorhinolaryngol* 1973; 20:434-43.
15
16
- 17 4. Epley JM. The Canalith Repositioning Procedure: For Treatment of Benign Paroxysmal
18
19 Positional Vertigo. *Otolaryngol Head Neck Surg* 1992; 107:399-404.
20
21
- 22 5. Brandt T, Steddin S. Current view of the mechanism of benign paroxysmal positioning vertigo:
23
24 cupulolithiasis or canalolithiasis? *J Vestib Res*1993; 3:373-82.
25
26
- 27 6. Inagaki T, Suzuki M, Otsuka K, *et al.* Model experiments of BPPV using isolated utricle and
28
29 posterior semicircular canal. *Auris Nasus Larynx* 2006; 33:129-34.
30
31
- 32 7. Bhattacharyya N, Gubbels SP, Schwartz SR, *et al.* Clinical practice guideline: benign
33
34 paroxysmal positional vertigo (Update). *Otolaryngol Head Neck Surg* 2017;156(3S):S1-47.
35
36
- 37 8. Martellucci S, Pagliuca G, de Vincentiis M, *et al.* Features of Residual Dizziness after Canalith
38
39 Repositioning Procedures for Benign Paroxysmal Positional Vertigo. *Otolaryngol Head Neck Surg*
40
41 2016; 49:74-78.
42
43
- 44 9. Swain SK BI, MC S. Role of Ginkgo biloba for controlling residual dizziness after successful
45
46 treatment of benign paroxysmal positional vertigo: Our experiences at a tertiary care teaching
47
48 hospital of Eastern India. *Int J health Allied Sci* 2018; 7:196-200.
49
50
- 51 10. Seok JI, MD, Lee HM, *et al.* Residual dizziness after successful repositioning treatment in
52
53 patients with benign paroxysmal positional vertigo. *J Clin Neurol* 2008; 3:107-16.
54
55
- 56 11. Giommetti G, Lapenna R, Panichi R, *et al.* Dizziness after Successful Repositioning Maneuver
57
58
59
60

- 1
2
3
4 for Idiopathic Benign Paroxysmal Positional Vertigo. *Audiol Res* 2017;178:31-7.
5
6
7 12. Vaduva C, Estéban-Sánchez J, Sanz-Fernández R, *et al.* Prevalence and management of post-
8
9 BPPV residual symptoms. *Eur Arch Otorhinolaryngol* 2018; 275:1429–1437
10
11
12 13. Lopez-Escamez JA, Gamiz MJ, Fernandez-Perez A, *et al.* Long-term outcome and health-
13
14 related quality of life in benign paroxysmal positional vertigo. *Eur Arch Otorhinolaryngol* 2005;
15
16 262:507-11.
17
18
19 14. Korres S, Balatsouras DG, Ferekidis E. Prognosis of patients with benign paroxysmal
20
21 positional vertigo treated with repositioning manoeuvres. *J Laryngol Otol* 2006; 120:528-33.
22
23
24 15. Faralli M, Lapenna R, Giommetti G, *et al.* Residual dizziness after the first BPPV episode: role
25
26 of otolithic function and of a delayed diagnosis. *Eur Arch Otorhinolaryngol* 2016, 273(10):1-9.
27
28
29 16. Seo T, Shiraishi K, Kobayashi T, *et al.* Residual dizziness after successful treatment of
30
31 idiopathic benign paroxysmal positional vertigo originates from persistent utricular dysfunction.
32
33
34
35
36
37
38 17. Kim HA, Lee H. Autonomic dysfunction as a possible cause of residual dizziness after
39
40 successful treatment in benign paroxysmal positional vertigo. *Clin Neurophysiol* 2014; 125:608-14.
41
42
43 18. Staab JP, Eckhardthenn A, Horii A, *et al.* Diagnostic criteria for persistent postural-perceptual
44
45 dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular
46
47 Disorders of the Bárány Society. *J Vestib Res* 2017; 27:1-18.
48
49
50 19. Rubenstein L Z, Kenny R A, Eccles M, *et al.* Preventing falls in older people: new advances
51
52 and the development of clinical practice guidelines. *JR Coll Physicians of Edinb* 2003;33:262-272.
53
54
55 20. Abou-Elew MH, Shabana MI, Selim MH, *et al.* Residual postural instability in benign
56
57 paroxysmal positional vertigo. *J Audiol Med* 2011; 9:8-15.
58
59
60

- 1
2
3
4 21. Teggi R, Quagliari S, Gatti O, *et al.* Residual Dizziness after Successful Repositioning
5
6 Maneuvers for Idiopathic Benign Paroxysmal Positional Vertigo. *Eur Arch Otorhinolaryngol* 2011;
7
8 268:507-11.
9
10
11 22. Vugt VAV, Horst HEVD, Payne RA, *et al.* Chronic vertigo: treat with exercise, not drugs. *BMJ*.
12
13 2017;358: j3727.
14
15
16 23. Guneri EA, Kustutan O. The effects of betahistine in addition to epley maneuver in posterior
17
18 canal benign paroxysmal positional vertigo. *Otolaryngol Head Neck Surg* 2012;146(1):104-08.
19
20
21 24. Acar B, Karasen RM, Buran Y. Efficacy of medical therapy in the prevention of residual
22
23 dizziness after successful repositioning maneuvers for Benign Paroxysmal Positional Vertigo
24
25 (BPPV). *B-ENT* 2015; 11:117-21.
26
27
28 25. Hillier SL, McDonnell M. Vestibular rehabilitation for unilateral peripheral vestibular
29
30 dysfunction. *Cochrane Db Syst Rev* 2011; 2: CD005397
31
32
33 26. Hall CD, Herdman SJ, Whitney SL, *et al.* Vestibular Rehabilitation for Peripheral Vestibular
34
35 Hypofunction: An Evidence-Based Clinical Practice Guideline: from the American physical therapy
36
37 association neurology section. *J Neurol Phys Ther* 2016; 40:124-55.
38
39
40 27. Shepard NT, Telian SA, Smithwheelock M. Habituation and balance retraining therapy: A
41
42 retrospective review. *Neurol Clin* 1990; 8:459-75.
43
44
45 28. Herdman SJ, Blatt PJ, Schubert MC. Vestibular rehabilitation of patients with vestibular
46
47 hypofunction or with benign paroxysmal positional vertigo. *Curr Opin Neurol* 2000; 13:39-43.
48
49
50 29. Bhattacharyya N, Gubbels SP, Schwartz SR, *et al.* Clinical practice guideline: benign
51
52 paroxysmal positional vertigo. *Otolaryngol Head Neck Surg* 2017;156: S1-47.
53
54
55 30. Hillier SL, McDonnell M. Vestibular rehabilitation for unilateral peripheral vestibular
56
57
58
59
60

dysfunction. *Clin Otolaryngol* 2011; 36:248-49.

31. Bressi F, Vella P, Casale M, *et al.* Vestibular rehabilitation in benign paroxysmal positional vertigo: Reality or fiction? *Int J Immunopathol Pharmacol* 2017; 30:113-22.

32. Chang WC, Yang YR, Hsu LC, *et al.* Balance improvement in patients with benign paroxysmal positional vertigo. *Clin Rehabil* 2008; 22:338-47.

33. Ribeiro KM, Freitas RV, Ferreira LM, *et al.* Effects of balance Vestibular Rehabilitation Therapy in elderly with Benign Paroxysmal Positional Vertigo: a randomized controlled trial. *Disabil Rehabil* 2017; 39:1198-206.

34. Otto V, Fischer B, Schwarz M, *et al.* Treatment of vertebrobasilar insufficiency--associated vertigo with a fixed combination of cinnarizine and dimenhydrinate. *Int Tinnitus J* 2008; 14:57-67.

35. Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. *Cochrane Db Syst Rev.* 2016;6: D10696.

36. Dziura JD, Post LA, Zhao Q, *et al.* Strategies for Dealing with Missing Data in Clinical Trials: From Design to Analysis. *Yale J Biol Med.* 2013; 86:343-58.

37. Grill E, Bronstein A, Furman J, *et al.* International Classification of Functioning, Disability and Health (ICF) Core Set for patients with vertigo, dizziness and balance disorders. *J Vestibul Res-Equil.* 2012; 22:261-71.

38. Alghwiri AA, Whitney SL, Baker CE, *et al.* The development and validation of the vestibular activities and participation measure. *Arch Phys Med Rehabil* 2012; 93:1822-31.

39. Mueller M, Whitney SL, Alghwiri A, *et al.* Subscales of the Vestibular Activities and Participation questionnaire could be applied across cultures. *J Clin Epidemiol* 2015;68: 211-19.

40. Nashner, LM. *Computerized dynamic posturography.* In: Jacobson GP SNE, editor *Balance*

1
2
3
4 *Function Assessment and Management*. San Diego: Plural Publishing; 2016.

5
6 41. Ding L, Liu C, Wang JX. An Evaluation of the Dizziness Handicap Inventory (Chinese
7
8 version). *Chinese Journal of Otolaryngology*. 2013;11:228-30. In Chinese
9

10
11 42. Hoseinabadi R, Pourbakht A, Yazdani N, *et al*. The effects of abnormality of cVEMP and
12
13 oVEMP on rehabilitation outcomes in patients with idiopathic benign paroxysmal positional vertigo.
14
15 *Eur Arch Otorhinolaryngol*. 2016; 273:643-48.
16
17

18
19 43. Tian Yongsheng, Zhang Yan, Ma Rong, *et al*. Features of vestibular evoked myogenic potential
20
21 in patients with residual dizziness after canalith repositioning procedures for benign paroxysmal
22
23 positional vertigo. *J Clin Otorhinolaryngol Head Neck Surg (China)* 2018; 32:845-49. In Chinese
24
25

26
27 44. Seo T, Shiraishi K, Kobayashi T, *et al*. Residual dizziness after successful treatment of
28
29 idiopathic benign paroxysmal positional vertigo originates from persistent utricular dysfunction.
30
31 *Acta Otolaryngol*. 2017; 137:1-4.
32
33

34
35 45. Zhou YJ, Wu YZ, Cong N, *et al*. Contrasting results of tests of peripheral vestibular function
36
37 in patients with bilateral large vestibular aqueduct syndrome. *Clin Neurophysiol*. 2017; 128:1513-
38
39

40 18
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author affiliations

1. Department of operation room, Eye and ENT Hospital of Fudan University, Shanghai, China
2. Intensive care unit, Eye and ENT Hospital of Fudan University, Shanghai, China
3. School of Nursing, Fudan University, Shanghai, China
4. Department of Otorhinolaryngology, Eye and ENT Hospital of Fudan University, Shanghai, China

Contributors All authors have made an intellectual contribution to this protocol. Li Huawei was the principal investigator of the trial, with full responsibility for the project. Wu PX, Cao WZ and Hu Yan conceived the design, developed the protocol, and wrote the first draft of this manuscript. Li Huawei and Hu Yan revised and approved the final version of the study protocol and the final manuscript. Li Huawei and Hu Yan are co-corresponding authors whom contributed this paper equally.

Funding This study was supported by Science and Technology Commission of Shanghai Municipality (grant number.184119551900) and the Department of Otorhinolaryngology at Eye & ENT Hospital of Fudan University.

Competing interests No competing interests exist.

Patients consent for publication Not required.

Ethics approval This study was approved by the Institute Review Board of Eye & ENT Hospital of Fudan University (reference number.2017046).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 Study flow chart.

Figure 2 Screenshot of head movement exercises in the training video.

Figure 3 Screenshot of gait exercise in the training video.

For peer review only




Figure 1 Study flow chart

254x190mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 2 Screenshot of head movement exercises in the training video

285x160mm (300 x 300 DPI)



Figure 3 Screenshot of gait exercises in the training video

528x297mm (96 x 96 DPI)